"","reason","nsnp"
"1","Abdominal aortic aneurysm (NA)",4
"2","Acenocoumarol maintenance dosage (NA)",2
"3","Acne (severe) (fixed effect model) (NA)",2
"4","Acne (severe) (NA)",3
"5","Activated partial thromboplastin time (unit increase)",8
"6","Acute lymphoblastic leukemia (adolescents and young adults) (NA)",1
"7","Acute lymphoblastic leukemia (B-cell precursor) (NA)",5
"8","Acute lymphoblastic leukemia (childhood) (ETV6-RUNX1 positive) (NA)",1
"9","Acute lymphoblastic leukemia (childhood) (ETV6-RUNX1 positive, Northern European) (NA)",2
"10","Acute lymphoblastic leukemia (childhood) (NA)",11
"11","ADAMTS13 activity (Conditional on rs41314453 and rs10456544) (unit increase)",1
"12","ADAMTS13 activity (unit increase)",2
"13","Addiction (NR unit increase) (NR unit increase)",1
"14","Adiponectin levels (log(ug/ml) increase) (log(ug/ml) increase)",1
"15","Adiponectin levels (NA)",1
"16","Adiponectin levels (ug/ml increase) (ug/ml increase)",4
"17","Adiponectin levels (unit increase) (unit increase)",20
"18","Adiposity (% increase) (% increase)",2
"19","Adiposity (z-score unit increase) (WC) (z-score unit increase)",1
"20","Adiposity (z-score unit increase) (WHR in women) (z-score unit increase)",1
"21","Adolescent idiopathic scoliosis (NA)",1
"22","Adolescent idiopathic scoliosis (severe) (NA)",1
"23","Adverse response to chemotherapy in breast cancer (alopecia) (Recessive) (NA)",2
"24","Age-related macular degeneration (CNV) (NA)",6
"25","Age-related macular degeneration (CNV vs. GA) (NA)",1
"26","Age-related macular degeneration (EA) (NA)",1
"27","Age-related macular degeneration (extreme sampling) (NA)",2
"28","Age-related macular degeneration (GA) (NA)",4
"29","Age-related macular degeneration (NA)",42
"30","Age-related macular degeneration (wet) (NA)",1
"31","Age-related nuclear cataracts (Random effect) (unit increase)",2
"32","Aging (facial) (NA)",1
"33","Aging (NA)",1
"34","Aging traits (age at natural menopause) (NA)",1
"35","AIDS progression (NA)",2
"36","Airflow obstruction (Smoker) (NA)",1
"37","Airflow obstruction (Smokers) (NA)",1
"38","Airway responsiveness in chronic obstructive pulmonary disease (unit increase) (Continous PC20) (unit increase)",1
"39","Alcohol and nictotine co-dependence (Combined, Australian replication) (NA)",1
"40","Alcohol and nictotine co-dependence (NA)",1
"41","Alcohol consumption (maxi-drinks) (unit increase)",1
"42","Alcohol consumption (NA)",1
"43","Alcohol consumption (transferrin glycosylation) (CDT concentration) (unit increase)",2
"44","Alcohol consumption (transferrin glycosylation) (CDT percent) (unit increase)",2
"45","Alcohol consumption (transferrin glycosylation) (Total transferrin) (unit increase)",2
"46","Alcohol consumption (unit increase) (quantile transformation) (unit increase)",1
"47","Alcohol consumption (unit increase) (unit increase)",4
"48","Alcohol dependence (age at onset) (NA)",3
"49","Alcohol dependence (NA)",4
"50","Allergic rhinitis (Latino) (NA)",3
"51","Allergic rhinitis (NA)",2
"52","Allergic sensitization (NA)",10
"53","Alopecia areata (NA)",6
"54","Alzheimer's disease (age of onset) (unit increase)",1
"55","Alzheimer's disease biomarkers (Cortical Ab) (NA)",5
"56","Alzheimer's disease biomarkers (unit increase) (ptau) (unit increase)",3
"57","Alzheimer's disease biomarkers (unit increase) (tau) (unit increase)",1
"58","Alzheimer's disease (cognitive decline) (unit increase)",13
"59","Alzheimer's disease in APOE e4+ carriers (NA)",2
"60","Alzheimer's disease (late onset) (Japanese) (NA)",1
"61","Alzheimer's disease (late onset) (NA)",34
"62","Alzheimer's disease (NA)",16
"63","Amyloid A serum levels (unit increase)",4
"64","Amyotrophic lateral sclerosis (NA)",7
"65","Amyotrophic lateral sclerosis (sporadic) (NA)",11
"66","Amyotrophic lateral sclerosis (years increase) (survival) (years increase)",2
"67","Androgen levels (DHT levels) (unit increase)",1
"68","Androgen levels (serum testosterone) (unit increase)",3
"69","Anger (Temperament) (unit increase)",1
"70","Angiotensin-converting enzyme activity (% variance)",2
"71","Ankle-brachial index (unit increase)",1
"72","Ankylosing spondylitis (less than) (NA)",1
"73","Ankylosing spondylitis (NA)",13
"74","Anterior chamber depth (unit increase)",1
"75","Anthropometric traits in newborns (Sum of Skinfolds, Model 2) (unit increase)",1
"76","Antibody status in Tripanosoma cruzi seropositivity (NA)",1
"77","Anticoagulant levels (SD increase) (PC) (SD increase)",1
"78","Antineutrophil cytoplasmic antibody-associated vasculitis (NA)",9
"79","Antinuclear antibody levels (unit increase)",1
"80","Antipsychotic drug-induced weight gain (NA)",1
"81","Aortic root size (cm increase)",5
"82","Aortic stiffness (unit increase)",1
"83","Aortic-valve calcification (NA)",1
"84","Apolipoprotein Levels (APOA2) (unit increase)",1
"85","Apolipoprotein Levels (APOB) (unit increase)",1
"86","Arsenic metabolism (DMA%) (NA)",1
"87","Arsenic metabolism (MMA%) (NA)",1
"88","Arthritis (juvenile idiopathic) (NA)",1
"89","Aspartate aminotransferase (NA)",1
"90","Aspirin hydrolysis (plasma) (NA)",1
"91","Asthma (Adult) (NA)",1
"92","Asthma and hay fever (NA)",10
"93","Asthma (childhood onset) (NA)",6
"94","Asthma (childhood onset) (unit increase) (unit increase)",2
"95","Asthma (corticosteroid response) (unit increase)",1
"96","Asthma (NA)",33
"97","Asymmetrical dimethylarginine levels (unit increase)",2
"98","Atopic dermatitis (NA)",21
"99","Atopic dermatitis (unit increase) (unit increase)",1
"100","Atrial fibrillation/atrial flutter (NA)",2
"101","Atrial fibrillation (NA)",14
"102","Attention deficit hyperactivity disorder (NA)",3
"103","Autism (NA)",3
"104","Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) (5 degree of freedom test) (NA)",3
"105","Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) (Modelling analysis) (NA)",10
"106","Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) (NA)",3
"107","Autism (Str) (NA)",1
"108","Autoimmune hepatitis type-1 (NA)",1
"109","Axial length (unit increase)",5
"110","Barrett's esophagus (NA)",2
"111","Basal cell carcinoma (NA)",17
"112","B cell non-Hodgkin lymphoma (NA)",1
"113","Behcet's disease (NA)",13
"114","Behcet's disease (Turkish cases with Uveitis - Recessive Model) (NA)",1
"115","Beta-2 microglubulin plasma levels (unit increase)",7
"116","Beta thalassemia/hemoglobin E disease (NA)",3
"117","Beta-trace protein levels (unit increase)",1
"118","Biliary atresia (NA)",1
"119","Bilirubin levels (bilirubin level increase) (bilirubin level increase)",4
"120","Bilirubin levels (bilirubin level increase) \(Conditional on rs11891311\) (bilirubin level increase)",1
"121","Bilirubin levels (mg/dL increase) (mg/dL increase)",1
"122","Bilirubin levels (s.d. increase) (s.d. increase)",3
"123","Bilirubin levels (umol/l increase in log(tbil) (umol/l increase in log(tbil)",2
"124","Bilirubin levels (unit increase) (Direct bilirubin) (unit increase)",1
"125","Bilirubin levels (unit increase) (Total bilirubin) (unit increase)",1
"126","Biochemical measures (umol/l increase) (umol/l increase)",1
"127","Biomedical quantitative traits (BD-RT) (NA)",1
"128","Biomedical quantitative traits (beats per minute increase) (beats per minute increase)",2
"129","Biomedical quantitative traits (increase) (increase)",1
"130","Bipolar disorder (addtive) (NA)",1
"131","Bipolar disorder and schizophrenia (NA)",2
"132","Bipolar disorder (body mass index interaction) (NA)",3
"133","Bipolar disorder (Latent Class 1) (NA)",1
"134","Bipolar disorder (Latent Class 2) (NA)",1
"135","Bipolar disorder (NA)",15
"136","Bipolar disorder or major depressive disorder (combined) (NA)",1
"137","Bipolar disorder (recessive) (NA)",1
"138","Birdshot chorioretinopathy (NA)",1
"139","Birth length (unit increase)",1
"140","Birth weight (gram increase) (gram increase)",6
"141","Birth weight (unit increase) (unit increase)",1
"142","Bitter taste perception (Caffeine) (unit increase)",1
"143","Bitter taste perception (PROP) (unit increase)",1
"144","Bitter taste perception (Quinine) (unit increase)",1
"145","Bitter taste response (NA)",1
"146","Black vs. blond hair color (hair color score increase)",5
"147","Black vs. red hair color (hair color score increase)",5
"148","Bladder cancer (Japanese) (NA)",1
"149","Bladder cancer (NA)",13
"150","Blond vs. brown hair color (NA)",5
"151","Blood and toenail selenium levels (NA)",12
"152","Blood metabolite levels (unit increase) (10-undecenoate (11:1n1)) (unit increase)",1
"153","Blood metabolite levels (unit increase) (1,5-anhydroglucitol (1,5-AG)) (unit increase)",2
"154","Blood metabolite levels (unit increase) (1-arachidonoylglycerophosphocholine) (unit increase)",1
"155","Blood metabolite levels (unit increase) (1-arachidonoylglycerophosphoethanolamine) (unit increase)",1
"156","Blood metabolite levels (unit increase) (1-arachidonoylglycerophosphoinositol) (unit increase)",1
"157","Blood metabolite levels (unit increase) (1-linoleoylglycerol (1-monolinolein)) (unit increase)",1
"158","Blood metabolite levels (unit increase) (1-methylurate) (unit increase)",1
"159","Blood metabolite levels (unit increase) (1-methylxanthine) (unit increase)",1
"160","Blood metabolite levels (unit increase) (1-palmitoylglycerophosphoethanolamine) (unit increase)",2
"161","Blood metabolite levels (unit increase) (1-stearoylglycerophosphoethanolamine) (unit increase)",1
"162","Blood metabolite levels (unit increase) (2-aminobutyrate) (unit increase)",2
"163","Blood metabolite levels (unit increase) (2-hydroxyisobutyrate) (unit increase)",1
"164","Blood metabolite levels (unit increase) (3-(4-hydroxyphenyl)lactate) (unit increase)",1
"165","Blood metabolite levels (unit increase) (3-dehydrocarnitine) (unit increase)",2
"166","Blood metabolite levels (unit increase) (3-phenylpropionate (hydrocinnamate)) (unit increase)",1
"167","Blood metabolite levels (unit increase) (4-acetamidobutanoate) (unit increase)",1
"168","Blood metabolite levels (unit increase) (4-androsten-3beta,17beta-diol disulfate 1) (unit increase)",1
"169","Blood metabolite levels (unit increase) (4-androsten-3beta,17beta-diol disulfate 2) (unit increase)",1
"170","Blood metabolite levels (unit increase) (5alpha-androstan-3beta,17beta-diol disulfate) (unit increase)",1
"171","Blood metabolite levels (unit increase) (5-oxoproline) (unit increase)",1
"172","Blood metabolite levels (unit increase) (acetylcarnitine) (unit increase)",2
"173","Blood metabolite levels (unit increase) (ADpSGEGDFXAEGGGVR) (unit increase)",2
"174","Blood metabolite levels (unit increase) (adrenate (22:4n6)) (unit increase)",1
"175","Blood metabolite levels (unit increase) (alpha-hydroxyisovalerate) (unit increase)",2
"176","Blood metabolite levels (unit increase) (androsterone sulfate) (unit increase)",3
"177","Blood metabolite levels (unit increase) (arachidonate (20:4n6)) (unit increase)",1
"178","Blood metabolite levels (unit increase) (asparagine) (unit increase)",1
"179","Blood metabolite levels (unit increase) (betaine) (unit increase)",3
"180","Blood metabolite levels (unit increase) (biliverdin) (unit increase)",1
"181","Blood metabolite levels (unit increase) (bradykinin, des-arg(9)) (unit increase)",2
"182","Blood metabolite levels (unit increase) (butyrylcarnitine) (unit increase)",2
"183","Blood metabolite levels (unit increase) (caffeine) (unit increase)",1
"184","Blood metabolite levels (unit increase) (carnitine) (unit increase)",4
"185","Blood metabolite levels (unit increase) (citrate) (unit increase)",3
"186","Blood metabolite levels (unit increase) (citrulline) (unit increase)",1
"187","Blood metabolite levels (unit increase) (cysteine-glutathione disulfide) (unit increase)",1
"188","Blood metabolite levels (unit increase) (decanoylcarnitine) (unit increase)",1
"189","Blood metabolite levels (unit increase) (dihomo-linolenate (20:3n3 or n6)) (unit increase)",2
"190","Blood metabolite levels (unit increase) (docosapentaenoate (n3 DPA; 22:5n3)) (unit increase)",1
"191","Blood metabolite levels (unit increase) (eicosapentaenoate (EPA; 20:5n3)) (unit increase)",1
"192","Blood metabolite levels (unit increase) (epiandrosterone sulfate) (unit increase)",1
"193","Blood metabolite levels (unit increase) (erythritol) (unit increase)",2
"194","Blood metabolite levels (unit increase) (erythronate) (unit increase)",1
"195","Blood metabolite levels (unit increase) (gamma-glutamylglutamine) (unit increase)",1
"196","Blood metabolite levels (unit increase) (glutaroyl carnitine) (unit increase)",5
"197","Blood metabolite levels (unit increase) (glycine) (unit increase)",1
"198","Blood metabolite levels (unit increase) (hexanoylcarnitine) (unit increase)",2
"199","Blood metabolite levels (unit increase) (histidine) (unit increase)",1
"200","Blood metabolite levels (unit increase) (homocitrulline) (unit increase)",1
"201","Blood metabolite levels (unit increase) (HWESASXX) (unit increase)",1
"202","Blood metabolite levels (unit increase) (hydroxyisovaleroyl carnitine) (unit increase)",1
"203","Blood metabolite levels (unit increase) (hypoxanthine) (unit increase)",1
"204","Blood metabolite levels (unit increase) (indolelactate) (unit increase)",1
"205","Blood metabolite levels (unit increase) (indolepropionate) (unit increase)",1
"206","Blood metabolite levels (unit increase) (inosine) (unit increase)",1
"207","Blood metabolite levels (unit increase) (isobutyrylcarnitine) (unit increase)",2
"208","Blood metabolite levels (unit increase) (isovalerylcarnitine) (unit increase)",2
"209","Blood metabolite levels (unit increase) (kynurenine) (unit increase)",2
"210","Blood metabolite levels (unit increase) (leucine) (unit increase)",1
"211","Blood metabolite levels (unit increase) (levulinate (4-oxovalerate)) (unit increase)",1
"212","Blood metabolite levels (unit increase) (lysine) (unit increase)",1
"213","Blood metabolite levels (unit increase) (mannose) (unit increase)",1
"214","Blood metabolite levels (unit increase) (myo-inositol) (unit increase)",2
"215","Blood metabolite levels (unit increase) (N-acetylornithine) (unit increase)",1
"216","Blood metabolite levels (unit increase) (octadecanedioate) (unit increase)",1
"217","Blood metabolite levels (unit increase) (octanoylcarnitine) (unit increase)",1
"218","Blood metabolite levels (unit increase) (oleoylcarnitine) (unit increase)",1
"219","Blood metabolite levels (unit increase) (pantothenate) (unit increase)",1
"220","Blood metabolite levels (unit increase) (phenylalanine) (unit increase)",1
"221","Blood metabolite levels (unit increase) (phenyllactate (PLA)) (unit increase)",1
"222","Blood metabolite levels (unit increase) (proline) (unit increase)",1
"223","Blood metabolite levels (unit increase) (propionylcarnitine) (unit increase)",1
"224","Blood metabolite levels (unit increase) (pyroglutamine) (unit increase)",2
"225","Blood metabolite levels (unit increase) (scyllo-inositol) (unit increase)",1
"226","Blood metabolite levels (unit increase) (serine) (unit increase)",2
"227","Blood metabolite levels (unit increase) (stearate (18:0)) (unit increase)",1
"228","Blood metabolite levels (unit increase) (stearidonate (18:4n3)) (unit increase)",1
"229","Blood metabolite levels (unit increase) (succinylcarnitine) (unit increase)",4
"230","Blood metabolite levels (unit increase) (tetradecanedioate) (unit increase)",1
"231","Blood metabolite levels (unit increase) (tryptophan betaine ) (unit increase)",1
"232","Blood metabolite levels (unit increase) (tryptophan) (unit increase)",2
"233","Blood metabolite levels (unit increase) (tyrosine) (unit increase)",1
"234","Blood metabolite levels (unit increase) (urate) (unit increase)",1
"235","Blood metabolite levels (unit increase) (uridine) (unit increase)",1
"236","Blood metabolite levels (unit increase) (X-02249) (unit increase)",1
"237","Blood metabolite levels (unit increase) (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide) (unit increase)",3
"238","Blood metabolite levels (unit increase) (X-03094) (unit increase)",3
"239","Blood metabolite levels (unit increase) (X-04499--3,4-dihydroxybutyrate) (unit increase)",1
"240","Blood metabolite levels (unit increase) (X-08402) (unit increase)",2
"241","Blood metabolite levels (unit increase) (X-09789) (unit increase)",1
"242","Blood metabolite levels (unit increase) (X-10395) (unit increase)",1
"243","Blood metabolite levels (unit increase) (X-10510) (unit increase)",1
"244","Blood metabolite levels (unit increase) (X-11247) (unit increase)",1
"245","Blood metabolite levels (unit increase) (X-11315) (unit increase)",1
"246","Blood metabolite levels (unit increase) (X-11423--O-sulfo-L-tyrosine) (unit increase)",1
"247","Blood metabolite levels (unit increase) (X-11440) (unit increase)",1
"248","Blood metabolite levels (unit increase) (X-11442) (unit increase)",1
"249","Blood metabolite levels (unit increase) (X-11444) (unit increase)",1
"250","Blood metabolite levels (unit increase) (X-11445--5-alpha-pregnan-3beta,20alpha-disulfate) (unit increase)",1
"251","Blood metabolite levels (unit increase) (X-11469) (unit increase)",2
"252","Blood metabolite levels (unit increase) (X-11470) (unit increase)",1
"253","Blood metabolite levels (unit increase) (X-11478) (unit increase)",1
"254","Blood metabolite levels (unit increase) (X-11529) (unit increase)",1
"255","Blood metabolite levels (unit increase) (X-11538) (unit increase)",1
"256","Blood metabolite levels (unit increase) (X-11550) (unit increase)",1
"257","Blood metabolite levels (unit increase) (X-11593--O-methylascorbate) (unit increase)",1
"258","Blood metabolite levels (unit increase) (X-11786--methylcysteine) (unit increase)",1
"259","Blood metabolite levels (unit increase) (X-11787) (unit increase)",1
"260","Blood metabolite levels (unit increase) (X-11792) (unit increase)",1
"261","Blood metabolite levels (unit increase) (X-11799) (unit increase)",1
"262","Blood metabolite levels (unit increase) (X-12038) (unit increase)",1
"263","Blood metabolite levels (unit increase) (X-12063) (unit increase)",1
"264","Blood metabolite levels (unit increase) (X-12092) (unit increase)",1
"265","Blood metabolite levels (unit increase) (X-12093) (unit increase)",1
"266","Blood metabolite levels (unit increase) (X-12095--N1-methyl-3-pyridone-4-carboxamide) (unit increase)",1
"267","Blood metabolite levels (unit increase) (X-12100--hydroxytryptophan) (unit increase)",1
"268","Blood metabolite levels (unit increase) (X-12244--N-acetylcarnosine) (unit increase)",4
"269","Blood metabolite levels (unit increase) (X-12441--12-hydroxyeicosatetraenoate (12-HETE)) (unit increase)",1
"270","Blood metabolite levels (unit increase) (X12442--5,8-tetradecadienoate) (unit increase)",1
"271","Blood metabolite levels (unit increase) (X-12510--2-aminooctanoic acid) (unit increase)",1
"272","Blood metabolite levels (unit increase) (X-12556) (unit increase)",2
"273","Blood metabolite levels (unit increase) (X-12627) (unit increase)",1
"274","Blood metabolite levels (unit increase) (X-12798) (unit increase)",2
"275","Blood metabolite levels (unit increase) (X-12844) (unit increase)",1
"276","Blood metabolite levels (unit increase) (X-12990--docosapentaenoic acid (n6-DPA)) (unit increase)",1
"277","Blood metabolite levels (unit increase) (X-13429) (unit increase)",1
"278","Blood metabolite levels (unit increase) (X-13431--nonanoylcarnitine) (unit increase)",2
"279","Blood metabolite levels (unit increase) (X-13435) (unit increase)",2
"280","Blood metabolite levels (unit increase) (X-13548) (unit increase)",1
"281","Blood metabolite levels (unit increase) (X-13671) (unit increase)",1
"282","Blood metabolite levels (unit increase) (X-14189--leucylalanine) (unit increase)",1
"283","Blood metabolite levels (unit increase) (X-14208--phenylalanylserine) (unit increase)",1
"284","Blood metabolite levels (unit increase) (X-14473) (unit increase)",1
"285","Blood metabolite levels (unit increase) (X-14625) (unit increase)",1
"286","Blood metabolite levels (unit increase) (X-18601) (unit increase)",1
"287","Blood metabolite levels (Urate levels) (NA)",1
"288","Blood metabolite levels (X12063 levels) (NA)",2
"289","Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438) (unit increase)",2
"290","Blood metabolite ratios (3-(4-hydroxyphenyl)lactate/alpha-hydroxyisovalerate) (unit increase)",1
"291","Blood metabolite ratios (4-acetamidobutanoate/N1-methyladenosine) (unit increase)",1
"292","Blood metabolite ratios (acetylcarnitine/hexanoylcarnitine) (unit increase)",1
"293","Blood metabolite ratios (ADpSGEGDFXAEGGGVR/X-14304--leucylalanine) (unit increase)",1
"294","Blood metabolite ratios (ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) (unit increase)",2
"295","Blood metabolite ratios (androsterone sulfate/4-androsten-3beta,17beta-diol disulfate 2) (unit increase)",2
"296","Blood metabolite ratios (androsterone sulfate/epiandrosterone sulfate) (unit increase)",1
"297","Blood metabolite ratios (arachidonate (20:4n6)/1-arachidonoylglycerophosphoinositol) (unit increase)",1
"298","Blood metabolite ratios (arachidonate (20:4n6)/dihomo-linolenate (20:3n3 or n6)) (unit increase)",1
"299","Blood metabolite ratios (aspartylphenylalanine/X-14450--phenylalanylleucine) (unit increase)",1
"300","Blood metabolite ratios (betaine/pyroglutamine) (unit increase)",1
"301","Blood metabolite ratios (carnitine/X-12798) (unit increase)",1
"302","Blood metabolite ratios (C-glycosyltryptophan/succinylcarnitine) (unit increase)",1
"303","Blood metabolite ratios (DHEA-S/4-androsten-3beta,17beta-diol disulfate 2) (unit increase)",1
"304","Blood metabolite ratios (docosapentaenoate (n3 DPA; 22:5n3)/X-12627) (unit increase)",1
"305","Blood metabolite ratios (DSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) (unit increase)",3
"306","Blood metabolite ratios (glucose/mannose) (unit increase)",1
"307","Blood metabolite ratios (glutamine/histidine) (unit increase)",1
"308","Blood metabolite ratios (hexanoylcarnitine/octanoylcarnitine) (unit increase)",1
"309","Blood metabolite ratios (indoleacetate/N2,N2-dimethylguanosine) (unit increase)",1
"310","Blood metabolite ratios (isoleucine/X-11529) (unit increase)",1
"311","Blood metabolite ratios (linoleate (18:2n6)/dihomo-linolenate (20:3n3 or n6)) (unit increase)",1
"312","Blood metabolite ratios (linoleate (18:2n6)/X-12442--5,8-tetradecadienoate) (unit increase)",1
"313","Blood metabolite ratios (lysine/glutaroyl carnitine) (unit increase)",2
"314","Blood metabolite ratios (Metabolite ratio 1) (unit increase)",1
"315","Blood metabolite ratios (myristate (14:0)/myristoleate (14:1n5)) (unit increase)",1
"316","Blood metabolite ratios (N-acetylornithine/myo-inositol) (unit increase)",1
"317","Blood metabolite ratios (octanoylcarnitine/X-13435) (unit increase)",1
"318","Blood metabolite ratios (phenyllactate (PLA)/phenylalanine) (unit increase)",1
"319","Blood metabolite ratios (phosphate/erythronate) (unit increase)",1
"320","Blood metabolite ratios (propionylcarnitine/isovalerylcarnitine) (unit increase)",1
"321","Blood metabolite ratios (urate/histidine) (unit increase)",1
"322","Blood metabolite ratios (valine/isovalerylcarnitine) (unit increase)",1
"323","Blood metabolite ratios (valine/proline) (unit increase)",1
"324","Blood metabolite ratios (X-04499--3,4-dihydroxybutyrate/C-glycosyltryptophan) (unit increase)",1
"325","Blood metabolite ratios (X-08402/cholesterol) (unit increase)",1
"326","Blood metabolite ratios (X-10510/palmitoyl sphingomyelin) (unit increase)",1
"327","Blood metabolite ratios (X-11315/pyroglutamine) (unit increase)",1
"328","Blood metabolite ratios (X-11440/4-androsten-3beta,17beta-diol disulfate 2) (unit increase)",1
"329","Blood metabolite ratios (X-11444/X-11470) (unit increase)",1
"330","Blood metabolite ratios (X-11444/X-12844) (unit increase)",1
"331","Blood metabolite ratios (X-11820/cholesterol) (unit increase)",1
"332","Blood metabolite ratios (X-12038/bradykinin, des-arg(9)) (unit increase)",1
"333","Blood metabolite ratios (X-12095--N1-methyl-3-pyridone-4-carboxamide/X-12844) (unit increase)",1
"334","Blood metabolite ratios (X-12798/phenylalanine) (unit increase)",1
"335","Blood metabolite ratios (X-13215/X-13671) (unit increase)",1
"336","Blood pressure measurement (cold pressor test) (MAP, Time 0) (mmHg increase)",1
"337","Blood pressure measurement (cold pressor test) (SBP, Time 0) (mmHg increase)",1
"338","Blood pressure measurement (high sodium and potassium intervention) (DBP, during intervention) (mmHg increase)",2
"339","Blood pressure measurement (high sodium and potassium intervention) (MAP, during intervention) (mmHg increase)",1
"340","Blood pressure measurement (high sodium and potassium intervention) (SBP, during intervention) (mmHg increase)",1
"341","Blood pressure measurement (high sodium intervention) (SBP, during intervention) (mmHg increase)",1
"342","Blood pressure measurement (low sodium intervention) (MAP, during intervention) (mmHg increase)",2
"343","Blood pressure measurement (low sodium intervention) (SBP, response to intervention) (mmHg increase)",1
"344","Blood pressure (mm Hg increase) (Diastolic) (mm Hg increase)",5
"345","Blood pressure (mmHg increase) (EA, DBP, Age 20-29) (mmHg increase)",1
"346","Blood pressure (mmHg increase) (EA, MAP, Age 40-49) (mmHg increase)",1
"347","Blood pressure (mmHg increase) (EA, MAP, Age 50-59) (mmHg increase)",1
"348","Blood pressure (mmHg increase) (EA, SBP, Age 50-59) (mmHg increase)",1
"349","Blood pressure (mmHg increase) (Mean Arterial Pressure) (mmHg increase)",21
"350","Blood pressure (mmHg increase) (Pulse Pressure) (mmHg increase)",7
"351","Blood pressure (mm Hg increase) (Systolic) (mm Hg increase)",4
"352","Blood pressure (SBPLTA) (NA)",1
"353","Blood pressure (smoking interaction) (SBP,Pack-years) (NA)",3
"354","Blood pressure (unit increase) (DBP) (unit increase)",4
"355","Blood pressure (unit increase) (SBP) (unit increase)",1
"356","Blood trace element (Cu levels) (unit increase)",2
"357","Blood trace element (Se levels) (NA)",1
"358","Blood trace element (Se levels) (unit increase) (unit increase)",1
"359","Blood trace element (Zn levels) (unit increase)",3
"360","Blue vs. brown eyes (NA)",1
"361","Blue vs. green eyes (NA)",4
"362","Body mass in chronic obstructive pulmonary disease (NA)",1
"363","Body mass index (change over time) (females) (unit increase)",1
"364","Body mass index in asthmatics (NA)",1
"365","Body mass index (% increase) (% increase)",4
"366","Body mass index (kg/m2 increase) (EA) (kg/m2 increase)",2
"367","Body mass index (kg/m2 increase) (EA, men) (kg/m2 increase)",1
"368","Body mass index (kg/m2 increase) (EA, women) (kg/m2 increase)",1
"369","Body mass index (kg/m2 increase) (kg/m2 increase)",54
"370","Body mass index (NA)",5
"371","Body mass index (% SD increase) (% SD increase)",8
"372","Body mass index (unit increase) (AA and Sub-Saharan) (unit increase)",3
"373","Body mass index (unit increase) (discovery + validation) (unit increase)",1
"374","Body mass index (unit increase) (rs11142387-C) (unit increase)",1
"375","Body mass index (unit increase) (unit increase)",23
"376","Body mass index (z score increase) (z score increase)",1
"377","Body mass (lean) (kg increase) (kg increase)",1
"378","Body mass (lean) (NA)",1
"379","Bone mineral density (FNK) (NA)",2
"380","Bone mineral density (hip) (NA)",3
"381","Bone mineral density (hip) (s.d. increase)",14
"382","Bone mineral density (mg/cm3 increase) (mg/cm3 increase)",2
"383","Bone mineral density (NA)",1
"384","Bone mineral density (paediatric, lower limb) (unit increase)",5
"385","Bone mineral density (paediatric, skull) (unit increase)",8
"386","Bone mineral density (paediatric, total body less head) (unit increase)",7
"387","Bone mineral density (paediatric, upper limb) (unit increase)",5
"388","Bone mineral density (SD increase) (SD increase)",1
"389","Bone mineral density (spine) (NA)",7
"390","Bone mineral density (spine) (s.d. increase)",21
"391","Bone mineral density (unit increase) (Conditional on rs917727) (unit increase)",1
"392","Bone mineral density (unit increase) (Cortical vBMD) (unit increase)",3
"393","Bone mineral density (unit increase) (femoral neck) (unit increase)",1
"394","Bone mineral density (unit increase) (FNBMD) (unit increase)",27
"395","Bone mineral density (unit increase) (hip, female) (unit increase)",1
"396","Bone mineral density (unit increase) (LSBMD) (unit increase)",31
"397","Bone mineral density (unit increase) (spine) (unit increase)",1
"398","Bone mineral density (unit increase) (Trabecular vBMD) (unit increase)",1
"399","Bone mineral density (unit increase) (unit increase)",2
"400","Bone properties (heel) (unit increase) (BUA) (unit increase)",4
"401","Bone properties (heel) (unit increase) (VOS) (unit increase)",5
"402","Brain connectivity (Clustering coefficient - L-isthmus of the cingulate) (NA)",1
"403","Brain connectivity (Clustering coefficient - R-insula) (NA)",2
"404","Brain connectivity (Strength - L-inferior parietal) (NA)",1
"405","Brain connectivity (Strength - L-transverse temporal) (NA)",1
"406","Brain connectivity (Strength - R-banks of the superior temporal sulcus) (NA)",1
"407","Brain connectivity (strength - R-inferior parietal) (NA)",1
"408","Brain connectivity (Strength - R paracentral) (NA)",1
"409","Brain connectivity (Strength - R-pars opercularis) (NA)",2
"410","Brain connectivity (unit increase) (unit increase)",1
"411","Brain structure (mm3 increase) (Intracranial volume) (mm3 increase)",1
"412","Brain structure (mm3 increase) (Mean bilateral hippocampal volume) (mm3 increase)",1
"413","Breast cancer (all races combined) (NA)",1
"414","Breast cancer (early onset) (NA)",18
"415","Breast cancer (East Asian) (NA)",3
"416","Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative) (NA)",2
"417","Breast Cancer in BRCA1 mutation carriers (NA)",2
"418","Breast cancer in BRCA2 mutation carriers (NA)",1
"419","Breast cancer (male) (NA)",2
"420","Breast cancer (NA)",82
"421","Breast cancer (survival) (ER -ve) (NA)",1
"422","Breast cancer (survival) (NA)",1
"423","Breast size (cup size increase)",6
"424","Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) (NA)",3
"425","Bronchodilator response in asthma (unit increase)",1
"426","Brugada syndrome (NA)",3
"427","B-type natriuretic peptide (unit increase)",2
"428","Butyrylcholinesterase levels (SD increase)",3
"429","C4b binding protein levels (NA)",1
"430","Caffeine consumption (mg/day increase)",2
"431","Calcium levels (unit increase) (unit increase)",10
"432","Cardiac hypertrophy (additive, recessive) (NA)",1
"433","Cardiac muscle measurement (Relative wall thickness) (NA)",1
"434","Cardiac repolarization (ms increase) (ms increase)",1
"435","Cardiac structure and function (LV internal diastolic dimensions) (cm increase)",1
"436","Cardiac Troponin-T levels (ug/L increase) (ug/L increase)",1
"437","Cardiovascular disease risk factors (mg/l increase) (mg/l increase)",1
"438","Cardiovascular disease risk factors (mmol/l increase) (HDL) (mmol/l increase)",2
"439","Cardiovascular disease risk factors (mmol/l increase) (LDL) (mmol/l increase)",4
"440","Cardiovascular disease risk factors (mmol/l increase) (TRIG) (mmol/l increase)",3
"441","Cardiovascular disease risk factors (% SD increase) (HDL-cholesterol) (% SD increase)",1
"442","Cardiovascular disease risk factors (% SD increase) (LDL-cholesterol) (% SD increase)",1
"443","Cardiovascular disease risk factors (umol/l increase) (umol/l increase)",4
"444","Cardiovascular disease risk factors (units/l increase) (BCHE) (units/l increase)",1
"445","Cardiovascular disease risk factors (units/l increase) (GGT) (units/l increase)",1
"446","Cardiovascular heart disease in diabetics (NA)",1
"447","Carotenoid and tocopherol levels (alpha-tocopherol) (umol/L increase)",1
"448","Carotenoid and tocopherol levels (beta-carotene) (umol/L increase)",1
"449","Carotid atherosclerosis in HIV infection (common cIMT) (NA)",1
"450","Carotid intima media thickness (unit increase) (cIMT) (unit increase)",3
"451","Carotid intima media thickness (unit increase) (Plaque) (unit increase)",2
"452","CD4:CD8 lymphocyte ratio (CD4:CD8) (SD increase)",1
"453","Celiac disease (NA)",33
"454","Celiac disease or Rheumatoid arthritis (NA)",11
"455","Central corneal thickness (SD increase) (SD increase)",2
"456","Central corneal thickness (unit increase) (unit increase)",6
"457","Cerebral amyloid angiopathy (unit increase)",1
"458","Cerebrospinal AB1-42 levels (Controls) (NA)",1
"459","Cerebrospinal AB1-42 levels in Alzheimer's disease dementia (unit increase)",2
"460","Cerebrospinal fluid levels of Alzheimer's disease-related proteins (Angiotensin-converting enzyme) (NA)",1
"461","Cerebrospinal fluid levels of Alzheimer's disease-related proteins (Interleukin-6 receptor) (NA)",1
"462","Cerebrospinal fluid levels of Alzheimer's disease-related proteins (Macrophage Inflammatory protein-1 beta) (NA)",1
"463","Cerebrospinal fluid levels of Alzheimer's disease-related proteins (Matrix metalloproteinase-3) (NA)",1
"464","Cerebrospinal fluid levels of Alzheimer's disease-related proteins (Monocyte chemotactic protein 1) (NA)",1
"465","Cerebrospinal T-tau levels (Controls) (NA)",1
"466","Cervical artery dissection (NA)",2
"467","Cervical cancer (Matched) (NA)",3
"468","Cervical cancer (NA)",2
"469","Cervical cancer (Stringently Matched) (NA)",1
"470","Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide) (NA)",1
"471","Cholelithiasis-related traits in sickle cell anemia (unit increase)",1
"472","Cholesterol (mg/dl increase between hmz)",1
"473","Cholesterol, total (mg/dL increase) (mg/dL increase)",13
"474","Cholesterol, total (s.d. increase) (s.d. increase)",12
"475","Cholesterol, total (unit increase) (unit increase)",63
"476","Chronic bronchitis and chronic obstructive pulmonary disease (EA, COPDGene + GenKOLS) (NA)",1
"477","Chronic bronchitis and chronic obstructive pulmonary disease (EA) (NA)",1
"478","Chronic bronchitis and chronic obstructive pulmonary disease (NA)",2
"479","Chronic hepatitis B infection (NA)",13
"480","Chronic hepatitis C infection (NA)",7
"481","Chronic kidney disease and serum creatinine levels (NA)",1
"482","Chronic kidney disease (CKD) (NA)",1
"483","Chronic kidney disease (eGFRcrea) (NA)",4
"484","Chronic kidney disease (eGFRcys) (NA)",1
"485","Chronic kidney disease (ml/min/1.73 m2 increase) (eGFRcrea) (ml/min/1.73 m2 increase)",15
"486","Chronic kidney disease (ml/min/1.73 m2 increase) (eGFRcys) (ml/min/1.73 m2 increase)",1
"487","Chronic kidney disease (ml/min/1.73m^2 increase) (ml/min/1.73m^2 increase)",2
"488","Chronic kidney disease (ml/min/1.73m2 increase) (ml/min/1.73m2 increase)",1
"489","Chronic kidney disease (NA)",1
"490","Chronic lymphocytic leukemia \(0.66\) (NA)",1
"491","Chronic lymphocytic leukemia (NA)",29
"492","Chronic myeloid leukemia (NA)",1
"493","Chronic obstructive pulmonary disease (moderate to severe) (NA)",4
"494","Chronic obstructive pulmonary disease (NA)",8
"495","Chronic obstructive pulmonary disease-related biomarkers (CC16) (NA)",5
"496","Chronic obstructive pulmonary disease-related biomarkers (SP-D) (NA)",12
"497","Chronic obstructive pulmonary disease (severe) (NA)",5
"498","Circulating cell-free DNA (ug/ml increase)",1
"499","Circulating myeloperoxidase levels (plasma) (unit increase)",2
"500","Circulating myeloperoxidase levels (serum) (unit increase)",3
"501","Circulating vasoactive peptide levels (nmol/l increase) (nmol/l increase)",1
"502","Circulating vasoactive peptide levels (pmol/l increase) (pmol/l increase)",3
"503","Classic bladder exstrophy (NA)",1
"504","Cleft lip (NA)",2
"505","Clozapine-induced cytotoxicity (30x) (NA)",2
"506","Coagulation factor levels (lU/dL increase)",1
"507","Cocaine dependence (Symptom count) (NA)",1
"508","Coffee consumption (cups per day increase) (cups per day increase)",2
"509","Coffee consumption (cups per day) (unit increase)",5
"510","Coffee consumption (unit increase) (unit increase)",5
"511","Cognitive decline (age-related) (unit increase)",2
"512","Cognitive decline (NA)",1
"513","Cognitive decline (unit increase) (unit increase)",1
"514","Cognitive function (unit increase)",5
"515","Cold medicine related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS-TEN) with severe mucosal involvement (NA)",1
"516","Colorectal cancer (diet interaction) (Processed meat) (NA)",1
"517","Colorectal cancer (distal colon cancer) (NA)",1
"518","Colorectal cancer (East Asian) (NA)",10
"519","Colorectal cancer (NA)",29
"520","Colorectal cancer (rs10795668) (NA)",1
"521","Common traits (Other) (asparagus anosmia) (NA)",1
"522","Common traits (Other) (sneeze) (NA)",1
"523","Common traits (Other) (unit increase) (unit increase)",3
"524","Complement C3 and C4 levels (Serum level of C3) (g/L increase)",2
"525","Complement C3 and C4 levels (Serum level of C4) (g/L increase)",8
"526","Conduct disorder (symptom count) (unit increase)",3
"527","Congenital heart disease (ASD) (NA)",1
"528","Congenital heart malformation (NA)",2
"529","Congenital left-sided heart lesions (EA) (NA)",1
"530","Contrast sensitivity (unit increase)",1
"531","Corneal astigmatism (NA)",1
"532","Corneal curvature (unit increase) (unit increase)",8
"533","Corneal structure (NA)",1
"534","Corneal structure (unit increase) (unit increase)",26
"535","Coronary arterial lesions in patients with Kawasaki disease (NA)",1
"536","Coronary artery calcification (% increase) (% increase)",2
"537","Coronary artery calcification (unit increase) (unit increase)",1
"538","Coronary artery disease (NA)",12
"539","Coronary artery disease or ischemic stroke (NA)",13
"540","Coronary artery disease or large artery stroke (NA)",17
"541","Coronary heart disease (NA)",48
"542","Cortical structure (interaction) (NA)",1
"543","Cortical thickness (mm increase)",3
"544","Cotinine glucuronidation (unit increase)",11
"545","C-reactive protein (AA women) (NA)",1
"546","C-reactive protein and white blood cell count (10^3/ul increase) (10^3/ul increase)",3
"547","C-reactive protein and white blood cell count (mg/dl increase) (mg/dl increase)",6
"548","C-reactive protein (% increase) (% increase)",5
"549","C-reactive protein levels (unit increase)",20
"550","C-reactive protein (log mg/dl increase) (log mg/dl increase)",1
"551","C-reactive protein (mg/dl increase) (mg/dl increase)",6
"552","C-reactive protein (mg/l increase in log(CRP) level) (mg/l increase in log(CRP) level)",1
"553","C-reactive protein (unit increase) (AA women) (unit increase)",4
"554","C-reactive protein (unit increase) (HA women) (unit increase)",2
"555","C-reactive protein (unit increase) (unit increase)",7
"556","Creatine kinase in statin users (unit increase)",2
"557","Creatinine levels (% increase) (% increase)",4
"558","Creatinine levels (NA)",1
"559","Creutzfeldt-Jakob disease (NA)",1
"560","Creutzfeldt-Jakob disease (sporadic) (NA)",1
"561","Creutzfeldt-Jakob disease (variant) (NA)",3
"562","Crohn's disease and celiac disease (NA)",2
"563","Crohn's disease and psoriasis (same-effect analysis) (NA)",2
"564","Crohn's disease (NA)",156
"565","Crohn's disease-related phenotypes (CDC stricturing) (NA)",1
"566","Cutaneous lupus erythematosus (NA)",3
"567","Cutaneous nevi (log nevus count increase) (log nevus count increase)",2
"568","Cystatin C (NA)",1
"569","Cystic fibrosis-related diabetes (NA)",1
"570","Cystic fibrosis severity \(p.Phe508del/p.Phe508del only\) (NA)",1
"571","D-dimer levels (% increase)",3
"572","Dehydroepiandrosterone sulphate levels (u mol/L increase) (u mol/L increase)",2
"573","Dehydroepiandrosterone sulphate levels (umol/L increase) (umol/L increase)",6
"574","Dementia and core Alzheimer's disease neuropathologic changes (Primary) (unit increase)",1
"575","Dengue shock syndrome (NA)",2
"576","Dental caries (DMFS2) (NA)",1
"577","Dental caries (DMFS5max, DMFS5) (NA)",1
"578","Diabetes (gestational) (NA)",2
"579","Diabetic retinopathy (NA)",4
"580","Diastolic blood pressure (mm Hg increase) (mm Hg increase)",9
"581","Diastolic blood pressure (mmHg increase) (mmHg increase)",17
"582","Diastolic blood pressure (unit increase) (unit increase)",9
"583","Dietary macronutrient intake (% increase) (Fat) (% increase)",1
"584","Dietary macronutrient intake (% increase) (Protein) (% increase)",1
"585","Dietary macronutrient intake (percent increase) (Protein - model 2) (percent increase)",1
"586","Diffuse large B cell lymphoma (NA)",5
"587","Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) (NA)",3
"588","Digit length ratio (NA)",1
"589","Diisocyanate-induced asthma (NA)",1
"590","Dilated cardiomyopathy (NA)",2
"591","Disc degeneration (lumbar) (NA)",1
"592","Disc degeneration (lumbar) (unit increase) (unit increase)",3
"593","DNA methylation (parent-of-origin) (H19-ICR-CpG02) (NA)",1
"594","DNA methylation (parent-of-origin) (H19-ICR CpG 09-10) (NA)",1
"595","DNA methylation (parent-of-origin) (KvDMR 10-11-12) (NA)",1
"596","DNA methylation (parent-of-origin) (KvDMR 21) (NA)",1
"597","DNA methylation (parent-of-origin) (NESPAS CpG08_09) (NA)",1
"598","DNA methylation (variation) (H19-ICR) (NA)",1
"599","DNA methylation (variation) (KvDMR) (NA)",1
"600","DNA methylation (variation) (NESPAS-ICR) (NA)",1
"601","Drinking behavior (NA)",3
"602","Drug-induced liver injury (amoxicillin-clavulanate) (NA)",2
"603","Drug-induced liver injury (flucloxacillin) (B*5701 positive) (NA)",1
"604","Drug-induced liver injury (flucloxacillin) (NA)",1
"605","Drug-induced liver injury (NA)",1
"606","Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) (NA)",3
"607","Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) (NW-EA) (NA)",1
"608","Duodenal ulcer (NA)",1
"609","Dupuytren's disease (NA)",9
"610","Educational attainment (NA)",3
"611","Educational attainment (unit increase) (Edu Years) (unit increase)",4
"612","Educational attainment (unit increase) (unit increase)",3
"613","Ejection fraction in Tripanosoma cruzi seropositivity (NA)",1
"614","Electrocardiographic conduction measures (msec increase) (msec increase)",5
"615","Electrocardiographic traits (ms increase) (QTc interval) (ms increase)",1
"616","Electrocardiographic traits (% s.d. increase) (HR) (% s.d. increase)",1
"617","Electrocardiographic traits (% s.d. increase) (PR interval) (% s.d. increase)",3
"618","Electrocardiographic traits (% s.d. increase) (QRS complex) (% s.d. increase)",1
"619","Electrocardiographic traits (% s.d. increase) (QRS duration) (% s.d. increase)",2
"620","Electrocardiographic traits (% s.d. increase) (QT interval) (% s.d. increase)",4
"621","Electrocardiographic traits (unit increase) (PR) (unit increase)",1
"622","Electrocardiographic traits (unit increase) (QT) (unit increase)",1
"623","Electroencephalographic traits in alcoholism (unit increase)",1
"624","Elevated serum carcinoembryonic antigen levels (NA)",12
"625","Endometrial cancer (NA)",1
"626","Endometriosis (NA)",8
"627","Endothelial growth factor levels (HGF) (unit increase)",1
"628","Endothelial growth factor levels (sTie-2) (unit increase)",2
"629","End-stage coagulation (D-dimer) (unit increase)",1
"630","End-stage coagulation (Fibrin lag time) (unit increase)",1
"631","End-stage coagulation (FVII:C) (unit increase)",5
"632","End-stage coagulation (FVIII) (unit increase)",1
"633","End-stage coagulation (FXIII activity) (unit increase)",2
"634","End-stage coagulation (FXIIIA) (unit increase)",7
"635","End-stage coagulation (FXIIIB) (unit increase)",1
"636","End-stage coagulation (FX) (unit increase)",1
"637","End-stage coagulation (vWF) (unit increase)",2
"638","End-stage renal disease in Type 1 diabetics (NA)",1
"639","End-stage renal disease (non-diabetic) (NA)",1
"640","Enteric fever (NA)",1
"641","Entorhinal cortical volume (Alzheimer's disease interaction) (unit increase)",1
"642","Eosinophil counts (% standard unit increase)",5
"643","Eosinophilic esophagitis (NA)",7
"644","Eosinophilic esophagitis (pediatric) (NA)",2
"645","Epilepsy (All epilepsy) (NA)",2
"646","Epilepsy (generalized) (All GGE) (NA)",2
"647","Epilepsy (generalized) (GAE) (NA)",1
"648","Epilepsy (generalized) (JME) (NA)",1
"649","Epilepsy (GGE) (NA)",2
"650","Epilepsy (NA)",1
"651","Epirubicin-induced leukopenia (NA)",1
"652","Episodic memory (unit increase)",1
"653","Epithelial ovarian cancer (NA)",13
"654","Epstein-Barr virus immune response (EBNA-1) (Conditional on rs477515 - Quantitative) (unit increase)",1
"655","Epstein-Barr virus immune response (EBNA-1) (Quantitative) (unit increase)",1
"656","Erythrocyte sedimentation rate (unit increase)",5
"657","E-selectin levels (ng/ml increase)",1
"658","Esophageal cancer  (alcohol interaction) (NA)",1
"659","Esophageal cancer and gastric cancer (ESCC) (NA)",2
"660","Esophageal cancer and gastric cancer (Total gastric) (NA)",1
"661","Esophageal cancer (NA)",11
"662","Esophageal cancer (squamous cell) (NA)",7
"663","Esophageal squamous cell cancer (length of survival) (NA)",1
"664","Esophageal squamous cell carcinoma (NA)",5
"665","Essential tremor (NA)",1
"666","Estradiol plasma levels (breast cancer) (unit increase)",1
"667","Ewing sarcoma (NA)",3
"668","Exfoliation glaucoma or exfoliation syndrome (NA)",2
"669","Exhaled carbon monoxide levels (unit increase)",1
"670","Expressive vocabulary in infants (15-18 months) (unit increase)",1
"671","Exudative age-related macular degeneration (NA)",7
"672","Eye color (NA)",2
"673","Eye color traits (% increase) (% increase)",2
"674","Eye color traits (NA)",1
"675","Eye color (unit increase) (eye color) (unit increase)",4
"676","Eye color (unit increase) (Eye color) (unit increase)",1
"677","Facial morphology (mm increase)",1
"678","Facial pigmentation (unit increase)",3
"679","Factor VIII levels (unit increase)",1
"680","Factor VII levels (NA)",1
"681","Factor VII (NA)",1
"682","Fasting glucose-related traits (FPG) (NA)",15
"683","Fasting glucose-related traits (HOMA-B) (NA)",1
"684","Fasting glucose-related traits (HOMA-IR) (NA)",1
"685","Fasting glucose-related traits (interaction with BMI) (NA)",22
"686","Fasting insulin (interaction) (Carbohydrate) (NA)",1
"687","Fasting insulin-related traits (HOMA-IR) (NA)",2
"688","Fasting insulin-related traits (interaction with BMI) (NA)",10
"689","Fasting plasma glucose (0.04-0.09) mmol/L increase) (0.04-0.09) mmol/L increase)",1
"690","Fasting plasma glucose (mmol/l increase) (mmol/l increase)",4
"691","Fasting plasma glucose (NA)",1
"692","Fasting plasma glucose (tFPG) (NA)",1
"693","Fasting plasma glucose (unit increase) (unit increase)",14
"694","Fat body mass (Adjusted by Lean body mass) (unit increase)",1
"695","Fat body mass (unit increase)",1
"696","F-cell distribution (% variance) (% variance)",2
"697","Febrile seizures (MMR-related vs MMR-unrelated) (NA)",3
"698","Febrile seizures (MMR vaccine-related) (NA)",4
"699","Febrile seizures (MMR vaccine-unrelated) (NA)",2
"700","Febrile seizures (Overall) (NA)",4
"701","Fetal hemoglobin levels in sickle cell anemia (unit increase)",2
"702","Fetal hemoglobin levels (s.d. increase in HbF) (s.d. increase in HbF)",2
"703","Fetal hemoglobin levels (unit increase) (African) (unit increase)",2
"704","Fibrinogen (g/L increase) (g/L increase)",8
"705","Fibrinogen (mg/dl increase) (mg/dl increase)",3
"706","Fibrinogen (unit increase) (EA) (unit increase)",21
"707","Fibrinogen (unit increase) (unit increase)",1
"708","Folate pathway vitamin levels (ng/ml increase) (vitamin B6) (ng/ml increase)",1
"709","Folate pathway vitamin levels (pg/ml increase) (pg/ml increase)",1
"710","Folate pathway vitamin levels (unit increase) (plasma homocysteine) (unit increase)",1
"711","Folate pathway vitamin levels (unit increase) (Plasma homocysteine) (unit increase)",1
"712","Folate pathway vitamin levels (unit increase) (Plasma PLP) (unit increase)",1
"713","Folate pathway vitamin levels (unit increase) (Plasma Vitamin B12) (unit increase)",2
"714","Follicular lymphoma (CLL/SLL) (NA)",1
"715","Follicular lymphoma (FL) (NA)",1
"716","Follicular lymphoma (NA)",8
"717","Follicule stimulating hormone (NA)",1
"718","Follicule stimulating hormone (unit increase) (unit increase)",1
"719","Forced vital capacity (EA) (ml increase)",6
"720","Fractional exhaled nitric oxide (childhood) (EA) (unit increase)",2
"721","Fractional exhaled nitric oxide (childhood) (unit increase)",3
"722","Freckles (NA)",3
"723","Freckling (unit increase)",4
"724","Frontotemporal dementia (All Frontotemporal dementia) (NA)",1
"725","Fuchs's corneal dystrophy (NA)",1
"726","Gallstones (NA)",1
"727","Gamma gluatamyl transferase levels (unit increase)",4
"728","Gamma glutamyl transpeptidase (IU/L increase)",7
"729","Gastric cancer (NA)",2
"730","Gene methylation in lung tissue (NA)",1
"731","Glaucoma (AA, incident) (NA)",1
"732","Glaucoma (AA) (NA)",2
"733","Glaucoma (AA, prevalent) (NA)",2
"734","Glaucoma (exfoliation) (NA)",1
"735","Glaucoma (high intraocular pressure) (NA)",1
"736","Glaucoma (Hispanic, incident) (NA)",1
"737","Glaucoma (NA)",4
"738","Glaucoma (primary angle closure) (NA)",3
"739","Glaucoma (primary open-angle) (NA)",10
"740","Glaucoma (primary open-angle) (NPG) (NA)",1
"741","Glioma (high-grade) (NA)",5
"742","Glioma (NA)",8
"743","Glomerular filtration rate (3-measure model) (unit increase)",1
"744","Glomerular filtration rate (3-measure Model) (unit increase)",1
"745","Glomerular filtration rate (6-measure model) (unit increase)",1
"746","Glomerular filtration rate (6-measure Model) (unit increase)",1
"747","Glomerular filtration rate (unit increase)",1
"748","Glomerulosclerosis (NA)",1
"749","Glucose homeostasis traits (AIRg) (unit increase)",1
"750","Glycated hemoglobin levels (% increase) (% increase)",13
"751","Glycated hemoglobin levels (unit increase) (HbA1c, Malay) (unit increase)",1
"752","Glycated hemoglobin levels (unit increase) (unit increase)",10
"753","Glycemic traits (1-hPG) (mmol-1 increase)",4
"754","Glycemic traits (FPG) (mmol-1 increase)",2
"755","Glycemic traits (pregnancy) (1HPG) (unit increase)",1
"756","Glycemic traits (pregnancy) (2HPG) (unit increase)",1
"757","Glycemic traits (pregnancy) (FCP) (unit increase)",2
"758","Glycemic traits (pregnancy) (FPG) (unit increase)",3
"759","Gout (NA)",7
"760","Gout (unit increase) (unit increase)",2
"761","Graves' disease (NA)",21
"762","Hair color (hair color) (NA)",1
"763","Hair color (NA)",1
"764","Hair color (unit increase) (red hair) (unit increase)",2
"765","Hair color (unit increase) (unit increase)",6
"766","Hair morphology (NA)",1
"767","Hair morphology (% variance) (% variance)",1
"768","Handedness in dyslexia (SD increase)",1
"769","Haptoglobin levels (SFS family cohort)",1
"770","Hashimoto thyroiditis versus Graves' disease (NA)",1
"771","HbA2 levels (NA)",2
"772","HDL cholesterol (mg/dl increase) (mg/dl increase)",6
"773","HDL cholesterol (mg/dL increase) (mg/dL increase)",19
"774","HDL cholesterol (mmol/l increase) (mmol/l increase)",2
"775","HDL cholesterol (percentage SD increase) (percentage SD increase)",3
"776","HDL cholesterol (s.d. increase) (s.d. increase)",14
"777","HDL Cholesterol - Triglycerides (HDLC-TG) (unit increase)",8
"778","HDL cholesterol (unit increase) (AA) (unit increase)",5
"779","HDL cholesterol (unit increase) (unit increase)",76
"780","Head circumference (infant) (SD increase)",2
"781","Hearing function (unit increase) (unit increase)",1
"782","Heart failure (EA) (NA)",1
"783","Heart rate (unit increase) (Conditional on rs1015451, rs11154027) (unit increase)",1
"784","Heart rate (unit increase) (Conditional on rs1015451, rs17083533) (unit increase)",1
"785","Heart rate (unit increase) (Conditonal on rs11118555) (unit increase)",1
"786","Heart rate (unit increase) (unit increase)",20
"787","Height adjusted BMI (unit increase)",2
"788","Height (cm increase) (cm increase)",15
"789","Height (Conditiond on rs2780226) (NA)",1
"790","Height (Conditioned on rs11107116) (NA)",1
"791","Height (Conditioned on rs1173727) (NA)",1
"792","Height (Conditioned on rs12153391) (NA)",1
"793","Height (Conditioned on rs2145998) (NA)",1
"794","Height (Conditioned on rs227724) (NA)",1
"795","Height (Conditioned on rs2780226) (NA)",1
"796","Height (Conditioned on rs3791675) (NA)",1
"797","Height (Conditioned on rs5742915) (NA)",1
"798","Height (Conditioned on rs6449353) (NA)",1
"799","Height (Conditioned on rs7689420) (NA)",1
"800","Height (males) (males)",14
"801","Height (NA)",59
"802","Height (% s.d. increase) (% s.d. increase)",12
"803","Height (s.d. increase) (s.d. increase)",6
"804","Height (unit increase) (unit increase)",418
"805","Helicobacter pylori serologic status (NA)",2
"806","Hematocrit (% increase)",8
"807","Hematological and biochemical traits (ALB) (unit increase)",1
"808","Hematological and biochemical traits (ALP) (unit increase)",4
"809","Hematological and biochemical traits (ALT) (unit increase)",2
"810","Hematological and biochemical traits (AST) (unit increase)",1
"811","Hematological and biochemical traits (BUN) (unit increase)",3
"812","Hematological and biochemical traits (CK) (unit increase)",1
"813","Hematological and biochemical traits (GGT) (unit increase)",2
"814","Hematological and biochemical traits (Hb) (unit increase)",1
"815","Hematological and biochemical traits (HDL) (unit increase)",3
"816","Hematological and biochemical traits (Ht) (unit increase)",1
"817","Hematological and biochemical traits (sCr) (unit increase)",1
"818","Hematological and biochemical traits (TP) (unit increase)",2
"819","Hematological parameters (10^12/l increase) (10^12/l increase)",1
"820","Hematological parameters (10^9/l increase) (PLT) (10^9/l increase)",3
"821","Hematological parameters (10^9/l increase) (WBC) (10^9/l increase)",1
"822","Hematological parameters (fl increase) (fl increase)",4
"823","Hematological parameters (pg increase) (pg increase)",1
"824","Hematology traits (s.d. increase) (MCH) (s.d. increase)",1
"825","Hematology traits (s.d. increase) (MCV) (s.d. increase)",2
"826","Hematology traits (s.d. increase) (PLT) (s.d. increase)",1
"827","Hematology traits (unit increase) (AA, HCT) (unit increase)",1
"828","Hematology traits (unit increase) (AA, RBC) (unit increase)",2
"829","Hematology traits (unit increase) (AA, WBC) (unit increase)",1
"830","Hematology traits (unit increase) (ALB/GLB) (unit increase)",2
"831","Hematology traits (unit increase) (EA, WBC) (unit increase)",1
"832","Hematology traits (unit increase) (HGB) (unit increase)",1
"833","Hematology traits (unit increase) (RBC) (unit increase)",1
"834","Hematology traits (unit increase) (WBC) (unit increase)",1
"835","Hemoglobin A2 levels in sickle cell anemia (NA)",1
"836","Hemoglobin (g/dl increase) (g/dl increase)",7
"837","Hemoglobin (NA)",1
"838","Hemostatic factors and hematological phenotypes (unit increase) (unit increase)",1
"839","Hepatitis B (NA)",7
"840","Hepatitis B vaccine response (NA)",4
"841","Hepatitis B (viral clearance) (Protective effects against CHB) (NA)",2
"842","Hepatitis C induced liver cirrhosis (NA)",5
"843","Hepatitis C induced liver fibrosis (Duration F0-1/F3-4, transfused) (NA)",1
"844","Hepatitis C induced liver fibrosis (QTF) (NA)",1
"845","Hepatitis (NA)",8
"846","Hepatocellular carcinoma (hepatitis B virus related) (NA)",2
"847","Hepatocellular carcinoma (NA)",5
"848","Hepcidin levels (Iron) (ng/ml increase)",1
"849","Hepcidin levels (Tf) (ng/ml increase)",1
"850","Hepcidin levels (Tf Sat) (ng/ml increase)",1
"851","Hereditary hemochromatosis-related traits (HFE mutation homozygotes) (Trasferrin) (unit increase)",1
"852","High serum lipase activity (NA)",1
"853","Hip circumference (psychosocial stress interaction) (EA) (NA)",1
"854","Hippocampal atrophy (Hippocampal volume) (NA)",2
"855","Hippocampal sclerosis of aging (NA)",1
"856","Hippocampal volume (mm3 increase) (mm3 increase)",3
"857","Hirschsprung disease (NA)",3
"858","HIV-1 control (AA) (NA)",4
"859","HIV-1 control (EA) (NA)",3
"860","HIV-1 control (% increase) (% increase)",1
"861","HIV-1 control (progression) (NA)",1
"862","HIV-1 susceptibility (NA)",1
"863","Hodgkin's lymphoma (EBV-negative cHL) (NA)",1
"864","Hodgkin's lymphoma (NA)",8
"865","Hodgkin's lymphoma (Total cHL) (NA)",2
"866","Homeostasis model assessment of beta-cell function (interaction) (n-6 PUFA) (NA)",2
"867","Homeostasis model assessment of insulin resistance (interaction) (Carbohydrate) (NA)",2
"868","Homoarginine levels (unit increase)",1
"869","Homocysteine levels (unit increase)",17
"870","Homocysteine levels (WGHS) (unit increase)",1
"871","Hormone measurements (unit increase) (Oestradiol) (unit increase)",2
"872","Hormone measurements (unit increase) (SHBG) (unit increase)",1
"873","HPV seropositivity (NA)",1
"874","Hyperopia (NA)",2
"875","Hypertension (log odds increase) (log odds increase)",1
"876","Hypertension (NA)",8
"877","Hypertension risk in short sleep duration (NA)",1
"878","Hypertension (unit increase) (unit increase)",6
"879","Hypertriglyceridemia (NA)",4
"880","Hypospadias (NA)",19
"881","Hypothyroidism (eMERGE) (NA)",1
"882","Hypothyroidism (NA)",5
"883","Idiopathic membranous nephropathy (NA)",20
"884","Idiopathic pulmonary fibrosis (NA)",5
"885","IFN-related cytopenia (NA)",1
"886","IgA nephropathy (EA) (NA)",1
"887","IgA nephropathy (East Asian) (NA)",1
"888","IgA nephropathy (NA)",19
"889","IgE grass sensitization (NA)",3
"890","IgE levels (% increase) (% increase)",1
"891","IgE levels (unit increase) (unit increase)",9
"892","IgG glycosylation (IGP14) (unit increase)",1
"893","IgG glycosylation (IGP17) (unit increase)",1
"894","IgG glycosylation (IGP23) (unit increase)",1
"895","IgG glycosylation (IGP26) (unit increase)",1
"896","IgG glycosylation (IGP29) (unit increase)",2
"897","IgG glycosylation (IGP2) (unit increase)",1
"898","IgG glycosylation (IGP31) (unit increase)",1
"899","IgG glycosylation (IGP38) (unit increase)",1
"900","IgG glycosylation (IGP39) (unit increase)",1
"901","IgG glycosylation (IGP40) (unit increase)",2
"902","IgG glycosylation (IGP41) (unit increase)",2
"903","IgG glycosylation (IGP42) (unit increase)",2
"904","IgG glycosylation (IGP53) (unit increase)",2
"905","IgG glycosylation (IGP59) (unit increase)",1
"906","IgG glycosylation (IGP63) (unit increase)",1
"907","IgG glycosylation (IGP67) (unit increase)",1
"908","IgG glycosylation (IGP69) (unit increase)",1
"909","IgG glycosylation (IGP70) (unit increase)",1
"910","IgG glycosylation (IGP72) (unit increase)",1
"911","IgG glycosylation (IGP7) (unit increase)",1
"912","IgG levels (NA)",1
"913","IgG levels (unit increase) (unit increase)",1
"914","IgM levels (NA)",1
"915","Immune reponse to smallpox (secreted IFN-alpha) (AA) (NA)",13
"916","Immune reponse to smallpox (secreted IFN-alpha) (EA) (NA)",4
"917","Immune reponse to smallpox (secreted IL-10) (AA) (NA)",3
"918","Immune reponse to smallpox (secreted IL-12p40) (EA) (NA)",4
"919","Immune reponse to smallpox (secreted IL-1beta) (AA) (NA)",3
"920","Immune reponse to smallpox (secreted IL-1beta) (EA) (NA)",4
"921","Immune reponse to smallpox (secreted IL-2) (AA) (NA)",5
"922","Immune reponse to smallpox (secreted IL-2) (EA) (NA)",3
"923","Immune reponse to smallpox (secreted TNF-alpha) (AA) (NA)",1
"924","Immune response to measles-mumps-rubella vaccine (IFN gamma response) (NA)",2
"925","Immune response to smallpox vaccine (IL-6) (AA) (NA)",8
"926","Immune response to smallpox vaccine (IL-6) (Hispanic) (NA)",2
"927","Immunoglobulin A (NA)",3
"928","Immunoglobulin G index levels in multiple sclerosis (unit increase)",2
"929","Infantile hypertrophic pyloric stenosis (NA)",4
"930","Infant length (unit increase)",11
"931","Inflammatory biomarkers (ESR) (NA)",2
"932","Inflammatory biomarkers (hsCRP-IL6 pattern prefenofibrate) (NA)",1
"933","Inflammatory biomarkers (hsCRP) (NA)",2
"934","Inflammatory biomarkers in Kawasaki disease (mg/dL increase)",1
"935","Inflammatory biomarkers (MCP-1) (NA)",2
"936","Inflammatory biomarkers (unit increase) (IL18) (unit increase)",2
"937","Inflammatory biomarkers (unit increase) (IL-1ra) (unit increase)",1
"938","Inflammatory bowel disease (early onset) (NA)",4
"939","Inflammatory bowel disease (NA)",113
"940","Inflammatory skin disease (Atopic dermatitis) (NA)",1
"941","Inflammatory skin disease (Opposed) (NA)",1
"942","Inflammatory skin disease (Psoriasis) (NA)",7
"943","Information processing speed (LDST/DSST- age, sex, and education adjusted) (unit increase)",1
"944","Insulin-like growth factors (IGFBP-3) (NA)",4
"945","Insulin-related traits (FI) (unit increase)",1
"946","Insulin-related traits (IR) (unit increase)",1
"947","Interferon alpha levels in systemic lupus erythematosus (EA) (NA)",1
"948","Interleukin-18 levels (NA)",2
"949","Interstitial lung disease (NA)",11
"950","Intracerebral hemorrhage (NA)",1
"951","Intracranial aneurysm (NA)",11
"952","Intracranial volume (ml increase)",2
"953","Intraocular pressure (mm Hg increase) (mm Hg increase)",8
"954","Intraocular pressure (mmHg increase) (mmHg increase)",1
"955","Intraocular pressure (unit increase) (unit increase)",1
"956","Iris characteristics (Crypts) (unit increase)",1
"957","Iris characteristics (Furrows) (unit increase)",1
"958","Iris characteristics (Pigmented Ring) (unit increase)",1
"959","Iris color (NA)",1
"960","Iron levels (ug/dL increase)",1
"961","Iron status biomarkers (ferritin levels) (unit increase)",5
"962","Iron status biomarkers (iron levels) (unit increase)",5
"963","Iron status biomarkers (mg/dl increase) (mg/dl increase)",1
"964","Iron status biomarkers (s.d. increase) (serum transferrin) (s.d. increase)",1
"965","Iron status biomarkers (transferrin levels) (unit increase)",9
"966","Iron status biomarkers (transferrin saturation) (NA)",2
"967","Iron status biomarkers (transferrin saturation) (unit increase)",4
"968","Iron status biomarkers (ug/dl increase) (ug/dl increase)",2
"969","Iron status biomarkers (unit increase) (ferritin) (unit increase)",1
"970","Iron status biomarkers (unit increase) (sTfR) (unit increase)",4
"971","Iron status biomarkers (unit increase) (TIBC) (unit increase)",2
"972","Ischemic stroke (NA)",1
"973","Kashin-Beck disease (NA)",1
"974","Kawasaki disease (NA)",8
"975","Keloid (NA)",3
"976","Kidney function decline traits (eGFRchange overall) (unit increase)",1
"977","Kidney stones (NA)",1
"978","Knee osteoarthritis (NA)",1
"979","Large artery stroke (NA)",1
"980","L-arginine levels (unit increase)",1
"981","Laryngeal squamous cell carcinoma (NA)",3
"982","LDL cholesterol (LDL) (NA)",1
"983","LDL cholesterol (mg/dl increase) (mg/dl increase)",3
"984","LDL cholesterol (mg/dL increase) (mg/dL increase)",9
"985","LDL cholesterol (mmol/L increase) (mmol/L increase)",1
"986","LDL cholesterol (NA)",1
"987","LDL cholesterol (percentage SD increase) (percentage SD increase)",4
"988","LDL cholesterol (% s.d. increase) (% s.d. increase)",1
"989","LDL cholesterol (s.d. increase) (s.d. increase)",13
"990","LDL cholesterol (unit increase) (AA) (unit increase)",5
"991","LDL cholesterol (unit increase) (unit increase)",54
"992","LDL (oxidized) (U/L increase)",1
"993","Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction) (Baseline, amyloid positive) (interaction)",1
"994","Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction) (Dilation, amyloid positive) (interaction)",2
"995","Leishmaniasis (visceral) (NA)",1
"996","Leprosy (NA)",26
"997","Lewy body disease (Ordinal I) (unit increase)",1
"998","Lifespan (unit increase)",1
"999","Lipid levels in hepatitis C treatment (NA)",1
"1000","Lipid metabolism phenotypes (Albumin) (unit increase)",1
"1001","Lipid metabolism phenotypes (APOB.assay, whole) (unit increase)",4
"1002","Lipid metabolism phenotypes (HDL-C.assay, fasting) (unit increase)",1
"1003","Lipid metabolism phenotypes (HDL-C.assay, whole) (unit increase)",2
"1004","Lipid metabolism phenotypes (HDL-C.by.NMR, whole) (unit increase)",1
"1005","Lipid metabolism phenotypes (HDL-C) (unit increase)",1
"1006","Lipid metabolism phenotypes (HDL.large, fasting) (unit increase)",1
"1007","Lipid metabolism phenotypes (HDL.large, whole) (unit increase)",1
"1008","Lipid metabolism phenotypes (HDL.total, whole) (unit increase)",1
"1009","Lipid metabolism phenotypes (IDL.total, whole) (unit increase)",1
"1010","Lipid metabolism phenotypes (LA/PUFA) (unit increase)",2
"1011","Lipid metabolism phenotypes (LDL-C.assay, fasting) (unit increase)",1
"1012","Lipid metabolism phenotypes (LDL-C.assay, whole) (unit increase)",2
"1013","Lipid metabolism phenotypes (LDL.large, whole) (unit increase)",1
"1014","Lipid metabolism phenotypes (LDL.total, fasting) (unit increase)",1
"1015","Lipid metabolism phenotypes (L-LDL-FC) (unit increase)",2
"1016","Lipid metabolism phenotypes (M-LDL-C/M-LDL-PL) (unit increase)",1
"1017","Lipid metabolism phenotypes (MobCH) (unit increase)",1
"1018","Lipid metabolism phenotypes (M-VLDL-PL) (unit increase)",1
"1019","Lipid metabolism phenotypes (TG.assay, whole) (unit increase)",1
"1020","Lipid metabolism phenotypes (Tot-C/Est-C) (unit increase)",1
"1021","Lipid metabolism phenotypes (Val/serum TG) (unit increase)",1
"1022","Lipid metabolism phenotypes (VLDL-D) (unit increase)",1
"1023","Lipid metabolism phenotypes (VLDL.medium, fasting) (unit increase)",1
"1024","Lipid metabolism phenotypes (VLDL.small, fasting) (unit increase)",2
"1025","Lipid metabolism phenotypes (VLDL.small, whole) (unit increase)",1
"1026","Lipid metabolism phenotypes (VLDL.total, fasting) (unit increase)",1
"1027","Lipid metabolism phenotypes (VLDL.total, whole) (unit increase)",1
"1028","Lipid metabolism phenotypes (XL-HDL-CE) (unit increase)",1
"1029","Lipid metabolism phenotypes (XL-HDL-TG) (unit increase)",2
"1030","Lipid metabolism phenotypes (XXL-VLDL-P) (unit increase)",1
"1031","Lipid traits (mmol/L increase) (HDL) (mmol/L increase)",3
"1032","Lipid traits (mmol/L increase) (LDL) (mmol/L increase)",2
"1033","Lipid traits (mmol/L increase) (TC) (mmol/L increase)",1
"1034","Lipid traits (mmol/L increase) (TG) (mmol/L increase)",1
"1035","Lipid traits (unit increase) (HDL-C) (unit increase)",3
"1036","Lipid traits (unit increase) (LDL-C) (unit increase)",2
"1037","Lipid traits (unit increase) (TG) (unit increase)",2
"1038","Lipid traits (unit increase) (Triglycerides) (unit increase)",1
"1039","Lipid traits (unit increase) (unit increase)",1
"1040","Lipoprotein (a) - cholesterol levels (NA)",14
"1041","Lipoprotein-associated phospholipase A2 activity and mass (ng/ml increase) (activity) (ng/ml increase)",6
"1042","Lipoprotein-associated phospholipase A2 activity and mass (ng/ml increase) (mass) (ng/ml increase)",1
"1043","Lipoprotein-associated phospholipase A2 activity and mass (nmol/ml/min increase) (nmol/ml/min increase)",3
"1044","Lipoprotein-associated phospholipase A2 activity and mass (unit increase) (Activity concentrations) (unit increase)",5
"1045","Lipoprotein-associated phospholipase A2 activity and mass (unit increase) (Mass concentrations) (unit increase)",2
"1046","Lipoprotein-associated phospholipase A2 activity change in response to statin therapy (percent increase) (percent increase)",2
"1047","Liver enzyme levels (alanine transaminase) (% increase) (% increase)",4
"1048","Liver enzyme levels (alkaline phosphatase) (% increase)",14
"1049","Liver enzyme levels (ALP) (U/L increase)",5
"1050","Liver enzyme levels (ALT) (U/L increase)",2
"1051","Liver enzyme levels (gamma-glutamyl transferase) (% increase)",26
"1052","Liver enzyme levels (GGT) (U/L increase)",2
"1053","Local histogram emphysema pattern (unit increase) (Moderate Centrilobular, EA) (unit increase)",1
"1054","Local histogram emphysema pattern (unit increase) (Moderate Centrilobular) (unit increase)",2
"1055","Local histogram emphysema pattern (unit increase) (normal) (unit increase)",3
"1056","Local histogram emphysema pattern (unit increase) (Panlobular) (unit increase)",2
"1057","Local histogram emphysema pattern (unit increase) (Severe Centrilobular) (unit increase)",2
"1058","Longevity (85 years and older) (NA)",1
"1059","Longevity (90 years and older) (NA)",2
"1060","Longevity (NA)",2
"1061","Lp (a) levels (mg/dl increase) (mg/dl increase)",1
"1062","Lp (a) levels (mg/dL increase) (mg/dL increase)",3
"1063","Lumiracoxib-related liver injury (NA)",1
"1064","Lung adenocarcinoma (NA)",9
"1065","Lung cancer (Adenocarcinoma) (NA)",1
"1066","Lung cancer (NA)",13
"1067","Lung cancer (Squamous cell carcinoma) (NA)",2
"1068","Lymphoma (FL) (NA)",4
"1069","Lymphoma (LYM) (NA)",1
"1070","Magnesium levels (mmol/L increase) (mmol/L increase)",6
"1071","Major depressive disorder (% improvement - 12 weeks) (NA)",1
"1072","Major depressive disorder (NA)",1
"1073","Major depressive disorder (unit increase) (% improvement - SSRI treated - 2 weeks) (unit increase)",1
"1074","Major mood disorders (NA)",1
"1075","Malaria (NA)",6
"1076","Male-pattern baldness (males) (NA)",1
"1077","Male-pattern baldness (NA)",10
"1078","Mammographic density (dense area) (NA)",1
"1079","Mammographic density (dense area) (unit increase) (unit increase)",7
"1080","Mammographic density (non-dense area) (unit increase) (unit increase)",1
"1081","Marginal zone lymphoma (NA)",2
"1082","Mathematical ability in children with dyslexia (% increase)",1
"1083","Matrix metalloproteinase levels (unit increase) (unit increase)",3
"1084","Mean corpuscular hemoglobin concentration (unit increase) (AA) (unit increase)",2
"1085","Mean corpuscular hemoglobin concentration (unit increase) (unit increase)",8
"1086","Mean corpuscular hemoglobin (pg increase) (pg increase)",9
"1087","Mean corpuscular hemoglobin (unit increase) (AA) (unit increase)",1
"1088","Mean corpuscular hemoglobin (unit increase) (unit increase)",19
"1089","Mean corpuscular volume (fl increase) (fl increase)",15
"1090","Mean corpuscular volume (unit increase) (AA) (unit increase)",2
"1091","Mean corpuscular volume (unit increase) (unit increase)",19
"1092","Mean platelet volume (10^9 L increase) (10^9 L increase)",7
"1093","Mean platelet volume (fl increase) (fl increase)",7
"1094","Mean platelet volume (fL increase) (fL increase)",2
"1095","Mean platelet volume (ln(fl) increase) (ln(fl) increase)",29
"1096","Mean platelet volume (per log fl increase) (per log fl increase)",1
"1097","Mean platelet volume (unit increase) (unit increase)",3
"1098","Melanoma (NA)",13
"1099","Menarche (age at onset) (months increase) (months increase)",1
"1100","Menarche (age at onset) (unit increase) (EA) (unit increase)",1
"1101","Menarche (age at onset) (unit increase) (unit increase)",117
"1102","Menarche (age at onset) (week increase) (week increase)",20
"1103","Menarche (age at onset) (year increase) (year increase)",1
"1104","Menarche and menopause (age at onset) (age at menarche) (years increase)",2
"1105","Menarche and menopause (age at onset) (age at natural menopause) (years increase)",3
"1106","Meningioma (NA)",1
"1107","Meningococcal disease (NA)",1
"1108","Menopause (age at onset) (years increase) (years increase)",20
"1109","Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS+FS vs. Controls) (NA)",1
"1110","Metabolic syndrome (bivariate traits) (BP-HDLC) (unit increase)",2
"1111","Metabolic syndrome (bivariate traits) (HDLC-GLUC) (unit increase)",3
"1112","Metabolic syndrome (bivariate traits) (HDLC-WC) (unit increase)",3
"1113","Metabolic syndrome (bivariate traits) (TG-GLUC) (unit increase)",4
"1114","Metabolic syndrome (cm increase) (cm increase)",1
"1115","Metabolic syndrome (mmHg increase) (SBP) (mmHg increase)",1
"1116","Metabolic syndrome (mmol/l increase) (GLU) (mmol/l increase)",5
"1117","Metabolic syndrome (mmol/l increase) (HDL) (mmol/l increase)",11
"1118","Metabolic syndrome (mmol/l increase) (TG) (mmol/l increase)",6
"1119","Metabolic syndrome (unit increase) (unit increase)",5
"1120","Metabolic traits (mmol/l increase) (CRP) (mmol/l increase)",2
"1121","Metabolic traits (mmol/l increase) (GLU) (mmol/l increase)",1
"1122","Metabolic traits (mmol/l increase) (TG) (mmol/l increase)",2
"1123","Metabolic traits (unit increase) (5-oxoproline) (unit increase)",1
"1124","Metabolic traits (unit increase) (alpha-hydroxyisovalerate + 6 other traits) (unit increase)",1
"1125","Metabolic traits (unit increase) (androsterone sulfate + 2 other traits) (unit increase)",1
"1126","Metabolic traits (unit increase) (aspartylphenylalanine) (unit increase)",1
"1127","Metabolic traits (unit increase) (bradykinin, des-arg(9)) (unit increase)",1
"1128","Metabolic traits (unit increase) (caffeine/quinate + 3 other traits) (unit increase)",1
"1129","Metabolic traits (unit increase) (carnitine) (unit increase)",1
"1130","Metabolic traits (unit increase) (decanoylcarnitine + 25 other traits) (unit increase)",1
"1131","Metabolic traits (unit increase) (glucose/mannose + 54 other traits) (unit increase)",1
"1132","Metabolic traits (unit increase) (glutamine + 7 other traits) (unit increase)",1
"1133","Metabolic traits (unit increase) (glutaroyl carnitine/lysine + 3 other traits) (unit increase)",1
"1134","Metabolic traits (unit increase) (glycine + 17 other traits) (unit increase)",1
"1135","Metabolic traits (unit increase) (inosine + 1 other trait) (unit increase)",1
"1136","Metabolic traits (unit increase) (isobutyrylcarnitine + 3 other traits) (unit increase)",1
"1137","Metabolic traits (unit increase) (isoleucine/tyrosine + 10 other traits) (unit increase)",1
"1138","Metabolic traits (unit increase) (isovalerylcarnitine + 7 other traits) (unit increase)",1
"1139","Metabolic traits (unit increase) (proline + 5 other traits) (unit increase)",1
"1140","Metabolic traits (unit increase) (serine) (unit increase)",1
"1141","Metabolic traits (unit increase) (SM-10 + 59 other traits) (unit increase)",1
"1142","Metabolic traits (unit increase) (SM-1 + 12 other traits) (unit increase)",1
"1143","Metabolic traits (unit increase) (SM-11 + 2 other traits) (unit increase)",1
"1144","Metabolic traits (unit increase) (SM-12 + 1 other trait) (unit increase)",1
"1145","Metabolic traits (unit increase) (SM-13) (unit increase)",1
"1146","Metabolic traits (unit increase) (SM-14 + 6 other traits) (unit increase)",1
"1147","Metabolic traits (unit increase) (SM-15 + 12 other traits) (unit increase)",1
"1148","Metabolic traits (unit increase) (SM-16 + 7 other traits) (unit increase)",1
"1149","Metabolic traits (unit increase) (SM-17 + 8 other traits) (unit increase)",1
"1150","Metabolic traits (unit increase) (SM-2 + 2 other traits) (unit increase)",1
"1151","Metabolic traits (unit increase) (SM-3 + 152 other traits) (unit increase)",1
"1152","Metabolic traits (unit increase) (SM-4 + 74 other traits) (unit increase)",1
"1153","Metabolic traits (unit increase) (SM-5 + 17 other traits) (unit increase)",1
"1154","Metabolic traits (unit increase) (SM-6 + 94 other traits) (unit increase)",1
"1155","Metabolic traits (unit increase) (SM-7 + 11 other traits) (unit increase)",1
"1156","Metabolic traits (unit increase) (SM-9 + 17 other traits) (unit increase)",1
"1157","Metabolic traits (unit increase) (succinylcarnitine) (unit increase)",1
"1158","Metabolic traits (unit increase) (urate, histidine) (unit increase)",1
"1159","Metabolite levels (2,6 dimethylheptanoyl carnitine) (NA)",1
"1160","Metabolite levels (Bilirubin) (NA)",1
"1161","Metabolite levels (C9H14Ona) (NA)",1
"1162","Metabolite levels (Caprolactam) (NA)",1
"1163","Metabolite levels (g/dL increase) (g/dL increase)",2
"1164","Metabolite levels (Glycerolphosphocholine) (NA)",2
"1165","Metabolite levels (Glycerophospho-N-Palmitoyl Ethanolamine) (NA)",1
"1166","Metabolite levels (Glycochenodeoxycholic acid 3-glucuronide) (NA)",1
"1167","Metabolite levels (IU/L increase) (IU/L increase)",2
"1168","Metabolite levels (mg/dL increase) (BUN) (mg/dL increase)",4
"1169","Metabolite levels (mg/dL increase) (FPG) (mg/dL increase)",4
"1170","Metabolite levels (mg/dL increase) (LDL) (mg/dL increase)",4
"1171","Metabolite levels (NA)",30
"1172","Metabolite levels (Pyroglutamine) (unit increase)",1
"1173","Metabolite levels (serine) (NA)",1
"1174","Metabolite levels (SM) (NA)",2
"1175","Metabolite levels (unit increase) (adrenate) (unit increase)",1
"1176","Metabolite levels (unit increase) (Ala, Gln) (unit increase)",1
"1177","Metabolite levels (unit increase) (Ala, Tyr) (unit increase)",1
"1178","Metabolite levels (unit increase) (Ala, Val) (unit increase)",1
"1179","Metabolite levels (unit increase) (betaine) (unit increase)",2
"1180","Metabolite levels (unit increase) (Citrate) (unit increase)",1
"1181","Metabolite levels (unit increase) (Fischer's ratio) (unit increase)",2
"1182","Metabolite levels (unit increase) (Glc) (unit increase)",2
"1183","Metabolite levels (unit increase) (Gln, Glc) (unit increase)",1
"1184","Metabolite levels (unit increase) (Gln, His) (unit increase)",1
"1185","Metabolite levels (unit increase) (glycine) (unit increase)",1
"1186","Metabolite levels (unit increase) (His, Val) (unit increase)",1
"1187","Metabolite levels (unit increase) (N-ACu) (unit increase)",1
"1188","Metabolite levels (unit increase) (Phe, Tyr) (unit increase)",1
"1189","Metabolite levels (unit increase) (Phe) (unit increase)",1
"1190","Metabolite levels (unit increase) (TMAu) (unit increase)",1
"1191","Metabolite levels (Unknown) (NA)",1
"1192","Metabolite levels (% variance) (C12/C10) (% variance)",1
"1193","Metabolite levels (% variance) (C14:1-OH/C10) (% variance)",1
"1194","Metabolite levels (% variance) (C3/C4) (% variance)",1
"1195","Metabolite levels (% variance) (C9/C10:2) (% variance)",1
"1196","Metabolite levels (% variance) (PC aa C36:3/PC aa C36:4) (% variance)",1
"1197","Metabolite levels  (X-11787) (unit increase)",2
"1198","Methotrexate clearance (acute lymphoblastic leukemia) (mL/min/m2 increase)",1
"1199","Methotrexate phramacokinetics (acute lymphoblastic leukemia) (mL/min/m2 increase) (mL/min/m2 increase)",1
"1200","Migraine - clinic-based (NA)",4
"1201","Migraine (NA)",13
"1202","Migraine without aura (NA)",5
"1203","Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection (NA)",2
"1204","Monocyte chemoattractant protein-1 (NA)",2
"1205","Monocyte count (EA) (unit increase)",4
"1206","Monocyte count (Japanese) (unit increase)",2
"1207","Monocyte count (unit increase)",5
"1208","Morbidity-free survival (NA)",2
"1209","Motion sickness (unit increase)",35
"1210","Moyamoya disease (NA)",1
"1211","Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma) (All Cancers) (NA)",2
"1212","Multiple myeloma (hyperdiploidy) (HD vs. controls) (NA)",4
"1213","Multiple myeloma (NA)",6
"1214","Multiple sclerosis (Cluxel size) (NA)",1
"1215","Multiple sclerosis (Conditioned on rs11581062) (NA)",1
"1216","Multiple sclerosis (Conditioned on rs17066096) (NA)",1
"1217","Multiple sclerosis (Conditioned on rs3118470) (NA)",1
"1218","Multiple sclerosis (Conditioned on rs4410871) (NA)",1
"1219","Multiple sclerosis (Conditioned on rs669607) (NA)",1
"1220","Multiple sclerosis (Conditioned on rs7238078) (NA)",1
"1221","Multiple sclerosis (Conditioned on rs9282641) (NA)",1
"1222","Multiple sclerosis (NA)",66
"1223","Multiple sclerosis (OCB status) (NA)",1
"1224","Multiple sclerosis (OCB status) (OCB positive vs. controls) (NA)",5
"1225","Musician's dystonia (NA)",1
"1226","Myasthenia gravis (NA)",3
"1227","Myeloproliferative neoplasms (NA)",1
"1228","Myocardial infarction (early onset) (NA)",9
"1229","Myocardial infarction (NA)",5
"1230","Myopia (NA)",1
"1231","Myopia (pathological) (mm increase) (mm increase)",1
"1232","Myopia (pathological) (NA)",35
"1233","Myopia (severe) (NA)",2
"1234","Narcolepsy (age of onset) (year increase)",3
"1235","Narcolepsy (NA)",6
"1236","Narcolepsy (onset before 2009 H1N1 influenza pandemic) (NA)",2
"1237","Narcolepsy with cataplexy (NA)",1
"1238","Nasopharyngeal carcinoma (NA)",9
"1239","Natriuretic peptide levels (unit increase)",1
"1240","Neonatal lupus (NA)",1
"1241","Nephrolithiasis (NA)",3
"1242","Nephropathy (NA)",6
"1243","Neuranatomic and neurocognitive phenotypes (NA)",1
"1244","Neuritic plaque (Case/control) (unit increase)",1
"1245","Neuritic plaque (Ordinal) (unit increase)",1
"1246","Neuroblastoma (high-risk) (NA)",1
"1247","Neuroblastoma (NA)",8
"1248","Neurofibrillary tangles (Ordinal I) (unit increase)",1
"1249","Neutrophil count in HIV-infection (unit increase)",1
"1250","Neutrophil count (NA)",1
"1251","Neutrophil count (unit increase) (EA) (unit increase)",1
"1252","Neutrophil count (unit increase) (unit increase)",3
"1253","Nevirapine-induced rash (NA)",1
"1254","N-glycan levels (DG11) (unit increase)",1
"1255","N-glycan levels (DG1) (unit increase)",1
"1256","N-glycan levels (DG6) (unit increase)",1
"1257","N-glycan levels (DG7) (unit increase)",1
"1258","N-glycan levels (DG9) (unit increase)",1
"1259","Nicotine dependence (cigarettes per day increase) (cigarettes per day increase)",1
"1260","Nicotine dependence (NA)",1
"1261","Nicotine glucouronidation (unit increase)",1
"1262","Non-albumin protein levels (ALB) (unit increase)",1
"1263","Non-albumin protein levels (NAP) (unit increase)",3
"1264","Non-alcoholic fatty liver disease histology (other) (unit increase) (Fibrosis) (unit increase)",1
"1265","Non-alcoholic fatty liver disease (NA)",1
"1266","Nonalcoholic fatty liver disease (unit increase) (unit increase)",1
"1267","Non-melanoma skin cancer (unit increase)",2
"1268","Non-obstructive azoospermia (NA)",4
"1269","Non-small cell lung cancer (NA)",1
"1270","Nonsyndromic cleft lip with or without cleft palate (NA)",5
"1271","Obesity (early onset extreme) (NA)",12
"1272","Obesity (extreme) (NA)",2
"1273","Obesity (NA)",6
"1274","Obesity (Obesity class III) (NA)",1
"1275","Obesity (Obesity class II) (NA)",12
"1276","Obesity (Obesity class I) (NA)",20
"1277","Obesity (Obesity II) (NA)",2
"1278","Obesity (Obesity I) (NA)",3
"1279","Obesity (obesity) (NA)",1
"1280","Obesity (Overweight) (NA)",13
"1281","Obesity-related traits (µIU/mL increase) (µIU/mL increase)",1
"1282","Obesity-related traits (kcal/d increase) (Total energy expenditure adj for weight ) (kcal/d increase)",1
"1283","Obesity-related traits (mg/dL increase) (GLU ) (mg/dL increase)",1
"1284","Obesity-related traits (mg/dL increase) (TG ) (mg/dL increase)",1
"1285","Obesity-related traits (min/d increase) (Sedentary&light activity ) (min/d increase)",1
"1286","Obesity-related traits (pg/mL increase) (MCP1 ) (pg/mL increase)",3
"1287","Obesity-related traits (SD increase) (hip) (SD increase)",1
"1288","Obesity-related traits (TFM) (NA)",1
"1289","Obesity (waist) (NA)",1
"1290","Obesity (WHR) (NA)",1
"1291","Odorant perception (&beta;-ionone) (unit increase)",1
"1292","Odorant perception (isobutyraldehyde) (unit increase)",1
"1293","Oleic acid (18:1n-9) plasma levels (unit increase)",1
"1294","Oligoclonal band status in multiple sclerosis (NA)",1
"1295","Opioid sensitivity (NA)",1
"1296","Optic cup area (EA) (unit increase)",7
"1297","Optic cup area (unit increase)",15
"1298","Optic disc area (mm2 increase) (Asian) (mm2 increase)",3
"1299","Optic disc area (unit increase) (EA) (unit increase)",1
"1300","Optic disc area (unit increase) (unit increase)",13
"1301","Optic disc parameters (mm increase)",3
"1302","Optic nerve measurement (disc area) (unit increase)",2
"1303","Orofacial clefts (interaction) (NA)",1
"1304","Orofacial clefts (Meta-All, NSCL/P) (NA)",9
"1305","Orofacial clefts (Meta-All, NSCLP) (NA)",1
"1306","Orofacial clefts (NA)",2
"1307","Ossification of the posterior longitudinal ligament of the spine (NA)",6
"1308","Osteoarthritis (hand, severe) (NA)",1
"1309","Osteoarthritis (hip) (Male-specifc) (NA)",1
"1310","Osteoarthritis (hip) (NA)",1
"1311","Osteoarthritis (mm increase) (mm increase)",1
"1312","Osteoarthritis (NA)",2
"1313","Osteoporosis (NA)",3
"1314","Osteoporosis-related phenotypes (g/cm2 increase) (LS BMD, women) (g/cm2 increase)",1
"1315","Osteoporosis-related phenotypes (NA)",1
"1316","Osteoprotegerin levels (Female-specific) (unit increase)",1
"1317","Osteoprotegerin levels (Sex-combined) (unit increase)",2
"1318","Osteosarcoma (NA)",2
"1319","Other erythrocyte phenotypes (1 M cell/mm^3 increase) (1 M cell/mm^3 increase)",1
"1320","Other erythrocyte phenotypes (1 M cells/mm^3 increase) (1 M cells/mm^3 increase)",1
"1321","Other erythrocyte phenotypes (g/dl increase) (g/dl increase)",2
"1322","Otitis media (chronic/recurrent) (NA)",1
"1323","Otosclerosis (NA)",1
"1324","Ovarian cancer (All invasive) (NA)",1
"1325","Ovarian cancer in BRCA1 mutation carriers (NA)",4
"1326","Ovarian cancer (NA)",2
"1327","Ovarian cancer (Serious invasive) (NA)",7
"1328","Paget's disease (NA)",9
"1329","Pain (onset time of analgesia) (NA)",1
"1330","Palmitic acid (16:0) plasma levels (unit increase)",1
"1331","Palmitoleic acid (16:1n-7) plasma levels (unit increase)",5
"1332","Pancreatic cancer (NA)",15
"1333","Pancreatitis (NA)",2
"1334","Panic disorder (NA)",1
"1335","Paraoxonase activity (Serum Arylesterase activity) (NA)",1
"1336","Paraoxonase activity (Serum Paraoxonases activity) (NA)",1
"1337","Parent of origin effect on language impairment (paternal) (unit increase) (unit increase)",1
"1338","Parkinson's disease (Asian) (NA)",2
"1339","Parkinson's disease (EA) (NA)",3
"1340","Parkinson's disease (NA)",50
"1341","Parkinson's disease (Sporadic) (NA)",1
"1342","PCA3 expression level (unit increase)",2
"1343","Peanut allergy (NA)",1
"1344","Percent mammographic density (% increase) (% increase)",1
"1345","Percent mammographic density (NA)",2
"1346","Percent mammographic density (unit increase) (unit increase)",2
"1347","Pericardial fat (NA)",1
"1348","Periodontitis (NA)",1
"1349","Permanent tooth development (unit increase)",4
"1350","Personality dimensions (unit increase) (Openness) (unit increase)",1
"1351","Personality traits in bipolar disorder (TCI-C1) (NA)",1
"1352","Personality traits in bipolar disorder (TCI-C3) (NA)",1
"1353","Personality traits in bipolar disorder (TCI-ST1) (NA)",1
"1354","Phospholipid levels (plasma) (ALA) (% increase)",1
"1355","Phospholipid levels (plasma) (a-linolenic acid) (% increase)",1
"1356","Phospholipid levels (plasma) (DHA) (% increase)",1
"1357","Phospholipid levels (plasma) (Docosapentaenoic acid) (% increase)",1
"1358","Phospholipid levels (plasma) (DPA) (% increase)",11
"1359","Phospholipid levels (plasma) (EPA) (% increase)",7
"1360","Phospholipid levels (plasma) (levels) (% increase)",14
"1361","Phospholipid levels (plasma) (Lower docosahexaenoic acid) (% increase)",1
"1362","Phospholipid levels (plasma) (proportions) (% increase)",10
"1363","Phosphorus levels (mg/dl increase) (mg/dl increase)",4
"1364","Phosphorus levels (unit increase) (unit increase)",1
"1365","Phytosterol levels (% increase)",2
"1366","Pit-and-Fissure caries (unit increase)",1
"1367","Plasma cystastin c levels in acute coronary syndrome (mg/L increase) (mg/L increase)",1
"1368","Plasma homocysteine levels (post-methionine load test) (NA)",1
"1369","Plasma homocysteine levels (post-methionine load test) (unit increase) (unit increase)",4
"1370","Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid) (unit increase)",1
"1371","Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) (Conditioned on rs174547) (unit increase)",1
"1372","Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) (unit increase)",3
"1373","Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid) (Conditioned on rs16966952) (unit increase)",1
"1374","Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid) (unit increase)",2
"1375","Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid) (unit increase) (unit increase)",2
"1376","Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid) (Conditioned on rs16966952) (unit increase)",1
"1377","Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid) (Conditioned on rs174547) (unit increase)",1
"1378","Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid) (unit increase)",3
"1379","Plasma plasminogen activator levels (unit increase)",4
"1380","Plasma plasminogen levels (Conditioned on rs4252129 and rs1084651) (unit increase)",1
"1381","Plasma plasminogen levels (unit increase)",3
"1382","Plasma renin activity levels (NA)",2
"1383","Plasma thyroid-stimulating hormone levels (uIU/L increase)",2
"1384","Plasminogen activator inhibitor type 1 levels (PAI-1) (unit increase)",3
"1385","Platelet aggregation (epinephrine) (NA)",2
"1386","Platelet count (10^9/l increase) (10^9/l increase)",53
"1387","Platelet count (unit increase) (unit increase)",11
"1388","Pneumoconiosis in silica exposure (NA)",1
"1389","Polycystic ovary syndrome (NA)",13
"1390","Post-traumatic stress disorder (asjusted for relatedness) (Whole cohort; EA) (NA)",1
"1391","Post-traumatic stress disorder (NA)",1
"1392","Post-traumatic stress disorder (Whole cohort; EA) (NA)",1
"1393","Primary biliary cirrhosis (NA)",27
"1394","Primary sclerosing cholangitis (NA)",2
"1395","Primary tooth development (number of teeth) (unit increase) (unit increase)",11
"1396","Primary tooth development (number of teeth) (% variance) (% variance)",4
"1397","Primary tooth development (time to first tooth eruption) (unit increase) (unit increase)",10
"1398","Primary tooth development (time to first tooth eruption) (% variance) (% variance)",3
"1399","PR interval in Tripanosoma cruzi seropositivity (NA)",5
"1400","PR interval (ms increase) (ms increase)",9
"1401","PR interval (unit increase) (Conditional) (unit increase)",2
"1402","PR interval (unit increase) (unit increase)",12
"1403","Progranulin levels (ng/ml increase)",1
"1404","Progressive supranuclear palsy (controlling for rs7571971) (NA)",1
"1405","Progressive supranuclear palsy (controlling for rs8070723) (NA)",1
"1406","Progressive supranuclear palsy (NA)",5
"1407","Proinsulin levels (NA)",9
"1408","Prostate cancer (All) (NA)",1
"1409","Prostate cancer (conditioned on rs9364554) (NA)",1
"1410","Prostate cancer (EA, early-onset) (NA)",1
"1411","Prostate cancer (EA) (NA)",9
"1412","Prostate cancer (early onset) (NA)",3
"1413","Prostate cancer (Japanese and Latin American) (NA)",1
"1414","Prostate cancer (Japanese) (NA)",2
"1415","Prostate cancer (NA)",93
"1416","Prostate cancer (unit increase) (unit increase)",4
"1417","Prostate-specific antigen levels (% increase) (% increase)",5
"1418","Prostate-specific antigen levels (unit increase) (unit increase)",7
"1419","Protein biomarker (unit increase)",1
"1420","Protein C levels (ug/ml increase) (ug/ml increase)",4
"1421","Protein C levels (unit increase) (Conditioned on rs7580658 and rs1799808) (unit increase)",2
"1422","Protein C levels (unit increase) (unit increase)",1
"1423","Protein quantitative trait loci (Alkaline phosphatase) (NA)",1
"1424","Protein quantitative trait loci (Ft3) (NA)",1
"1425","Protein quantitative trait loci (IL18) (NA)",1
"1426","Protein quantitative trait loci (LPA) (NA)",1
"1427","Protein quantitative trait loci (MIPb) (NA)",1
"1428","Protein quantitative trait loci (sIL-6R) (NA)",1
"1429","Protein quantitative trait loci (Soluble transferrin receptor) (NA)",1
"1430","Prothrombin time (unit increase)",2
"1431","PR segment (unit increase)",8
"1432","Psoriasis (NA)",31
"1433","Psoriatic arthritis (NA)",4
"1434","Psychosis and Alzheimer's disease (NA)",1
"1435","Pubertal anthropometrics (Late pubertal growth) (unit increase)",1
"1436","Pubertal anthropometrics (Pubertal growth, females) (unit increase)",1
"1437","Pubertal anthropometrics (Pubertal growth) (unit increase)",1
"1438","Pubertal anthropometrics (Single Height) (unit increase)",1
"1439","Puberty onset (genital enlargement) (unit increase)",1
"1440","Puberty onset (unit increase)",1
"1441","Pulmonary arterial hypertension (without BMPR2 mutations) (NA)",1
"1442","Pulmonary artery enlargement and chronic obstructive pulmonary disease (NA)",1
"1443","Pulmonary artery enlargement in chronic obstructive pulmonary disease (NA)",2
"1444","Pulmonary emphysema (Chinese) (unit increase)",2
"1445","Pulmonary emphysema (Hispanic) (unit increase)",1
"1446","Pulmonary function (FEV1/FVC) (NA)",1
"1447","Pulmonary function (% increase) (% increase)",4
"1448","Pulmonary function (% increase in FEV1/FVC ratio) (% increase in FEV1/FVC ratio)",1
"1449","Pulmonary function (interaction) (FEV1, Ever-smoking) (NA)",2
"1450","Pulmonary function (interaction) (FEV1/FVC, Ever-smoking) (NA)",8
"1451","Pulmonary function (interaction) (FEV1/FVC, Pack-years) (NA)",6
"1452","Pulmonary function (interaction) (unit increase) (FEV1, Ever-smoking) (unit increase)",1
"1453","Pulmonary function (interaction) (unit increase) (FEV1/FVC, Ever-smoking) (unit increase)",1
"1454","Pulmonary function (interaction) (unit increase) (FEV1/FVC, Pack-years) (unit increase)",1
"1455","Pulmonary function (ml increase) (ml increase)",1
"1456","Pulmonary function (s.d. increase) (FEV1/FVC) (s.d. increase)",3
"1457","Pulmonary function (s.d. increase) (FEV1) (s.d. increase)",3
"1458","Pulmonary function (unit increase) (FEV1/FVC) (unit increase)",13
"1459","Pulmonary function (unit increase) (FEV1) (unit increase)",3
"1460","P wave duration (unit increase)",3
"1461","QRS duration (ms increase) (ms increase)",12
"1462","QRS duration (unit increase) (unit increase)",3
"1463","QT interval (msec increase) (msec increase)",9
"1464","QT interval (ms increase) (ms increase)",10
"1465","QT interval (NA)",1
"1466","QT interval (unit increase) (unit increase)",72
"1467","Quantitative traits (mg/dL increase) (TG) (mg/dL increase)",1
"1468","Reading or mathematical ability (unit increase)",1
"1469","Recombination measurement (African-enrichment) (NA)",2
"1470","Recombination measurement (females) (NA)",1
"1471","Recombination measurement (Hotspot usage) (NA)",1
"1472","Recombination measurement (males) (NA)",1
"1473","Recombination rate (females) (cM increase)",1
"1474","Recombination rate (males) (cM increase)",1
"1475","Red blood cell count (unit increase)",8
"1476","Red blood cell fatty acid levels (AA) (unit increase)",2
"1477","Red blood cell fatty acid levels (ALA) (unit increase)",1
"1478","Red blood cell fatty acid levels (DGLA) (unit increase)",1
"1479","Red blood cell fatty acid levels (DPA-n3) (unit increase)",1
"1480","Red blood cell fatty acid levels (DTA) (unit increase)",1
"1481","Red blood cell fatty acid levels (GLA) (unit increase)",1
"1482","Red blood cell fatty acid levels (LA) (unit increase)",2
"1483","Red blood cell fatty acid levels (OA) (unit increase)",3
"1484","Red blood cell traits (d/dL increase) (d/dL increase)",1
"1485","Red blood cell traits (g/dL increase) (Hgb, AA) (g/dL increase)",1
"1486","Red blood cell traits (g/dL increase) (MCHC, AA) (g/dL increase)",1
"1487","Red blood cell traits (% increase) (Ht, AA) (% increase)",1
"1488","Red blood cell traits (NA)",1
"1489","Red blood cell traits (pg increase) (MCH, AA) (pg increase)",2
"1490","Red blood cell traits (pg increase) (MCH) (pg increase)",1
"1491","Red blood cell traits (unit increase) (EA, Hgb) (unit increase)",4
"1492","Red blood cell traits (unit increase) (EA, MCHC) (unit increase)",2
"1493","Red blood cell traits (unit increase) (EA, MCH) (unit increase)",10
"1494","Red blood cell traits (unit increase) (EA, MCV) (unit increase)",16
"1495","Red blood cell traits (unit increase) (EA, PCV) (unit increase)",2
"1496","Red blood cell traits (unit increase) (EA, RBCC) (unit increase)",5
"1497","Red blood cell traits (unit increase) (EA, RBCC\) (unit increase)",1
"1498","Red blood cell traits (unit increase) (Hgb) (unit increase)",1
"1499","Red blood cell traits (unit increase) (MCHC) (unit increase)",2
"1500","Red blood cell traits (unit increase) (MCH) (unit increase)",4
"1501","Red blood cell traits (unit increase) (MCV) (unit increase)",1
"1502","Red blood cell traits (unit increase) (PCV) (unit increase)",1
"1503","Red blood cell traits (unit increase) (RBC count) (unit increase)",1
"1504","Red blood cell traits (x10^6/uL, increase) (x10^6/uL, increase)",1
"1505","Red vs non-red hair color (NA)",1
"1506","Refractive astigmatism (EA, 25 years or older) (NA)",1
"1507","Refractive error (diopter increase) (diopter increase)",2
"1508","Refractive error (unit increase) (unit increase)",25
"1509","Relative hand skill in reading disability (unit increase)",1
"1510","Renal cell carcinoma (NA)",5
"1511","Renal cell carcinoma (Western European) (NA)",2
"1512","Renal function and chronic kidney disease (ml/min/1.73m2 increase) (ml/min/1.73m2 increase)",3
"1513","Renal function-related traits (BUN) (mg/dl increase)",13
"1514","Renal function-related traits (eGRFcrea) (ml/min/1.73m2 increase)",7
"1515","Renal function-related traits (sCR) (mg/dl increase)",8
"1516","Renal function-related traits (urea) (mg/dl increase)",4
"1517","Renal transplant outcome (unit increase)",1
"1518","Resistin levels (unit increase) (unit increase)",2
"1519","Response to alcohol consumption (flushing response) (unit increase)",1
"1520","Response to antidepressants (unit increase) (nortriptyline) (unit increase)",1
"1521","Response to antipsychotic therapy (extrapyramidal side effects) (SAS) (NA)",1
"1522","Response to antipsychotic treatment (Effect of Quetiapine on PGI) (NA)",1
"1523","Response to antipsychotic treatment (Effect of Risperidone on CGI-S) (NA)",1
"1524","Response to antipsychotic treatment (olanzapine-hemoglobin A1c\) (NA)",1
"1525","Response to antipsychotic treatment (risperidone-hip circumference) (NA)",1
"1526","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) (Hispanic) (NA)",1
"1527","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) (EA) (NA)",4
"1528","Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) (Hispanic) (NA)",4
"1529","Response to bleomycin (chromatid breaks) (unit increase)",1
"1530","Response to citalopram treatment (EA + AA - Vision\hearing) (NA)",1
"1531","Response to clopidogrel therapy (NA)",1
"1532","Response to Dalcetrapib treatment in acute coronary syndrome (NA)",1
"1533","Response to fenofibrate (VLDL diameter) (unit increase)",1
"1534","Response to gemcitabine in pancreatic cancer (NA)",1
"1535","Response to hepatitis C treatment (Change in Hb) (NA)",1
"1536","Response to hepatitis C treatment (Change of Hb) (NA)",1
"1537","Response to hepatitis C treatment (combined, EA) (NA)",1
"1538","Response to hepatitis C treatment (NA)",1
"1539","Response to inhaled glucocorticoid treatment in asthma (percentage change of FEV1) (NA)",2
"1540","Response to interferon beta therapy (unit increase)",2
"1541","Response to metformin in type 2 diabetes (glycemic) (NA)",1
"1542","Response to metformin (NA)",1
"1543","Response to radiotherapy in cancer (late toxicity) (unit increase) (Prostate cancer, rectal incontinence, univariable analysis) (unit increase)",1
"1544","Response to radiotherapy in prostate cancer (toxicity) (unit increase)",1
"1545","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DCT/S-CT ratio, adjusted for CYP2C19) (NA)",1
"1546","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DCT/S-CT ratio) (NA)",1
"1547","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DDCT concentration) (NA)",2
"1548","Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DDCT/S-DCT ratio) (NA)",1
"1549","Response to statins (LDL cholesterol change) (unit increase)",2
"1550","Response to statin therapy (chol, diff) (NA)",1
"1551","Response to statin therapy (HDL, sum) (NA)",1
"1552","Response to statin therapy (LDL-C) (% increase) (% increase)",2
"1553","Response to statin therapy (LDL-C) (mg/dL increase) (baseline LDL-C) (mg/dL increase)",2
"1554","Response to statin therapy (mmol/L increase) (mmol/L increase)",1
"1555","Response to statin therapy (NA)",1
"1556","Response to tamoxifen in breast cancer (NA)",1
"1557","Response to temozolomide (NA)",1
"1558","Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine) (NA)",1
"1559","Response to tocilizumab in rheumatoid arthritis (CSJC , EA, RF-) (unit increase)",1
"1560","Response to Vitamin E supplementation (mg/L increase) (mg/L increase)",1
"1561","Resting heart rate (ms increase) (ms increase)",8
"1562","Resting heart rate (ms increase) \(Random effects analysis\) (ms increase)",1
"1563","Resting heart rate (NA)",2
"1564","Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry) (unit increase)",1
"1565","Restless legs syndrome (NA)",9
"1566","Retinal arteriolar caliber (unit increase)",2
"1567","Retinal vascular caliber (um increase)",4
"1568","Retinol levels (ug/L increase)",2
"1569","Rheumatoid arthritis (ACPA+ cases vs. all controls) (NA)",5
"1570","Rheumatoid arthritis (ACPA-negative) (NA)",2
"1571","Rheumatoid arthritis (ACPA-positive RA vs ACPA-negative RA) (NA)",2
"1572","Rheumatoid arthritis (ACPA-positive RA vs controls) (NA)",1
"1573","Rheumatoid arthritis (EA) (NA)",25
"1574","Rheumatoid arthritis (East Asian) (NA)",2
"1575","Rheumatoid arthritis (NA)",92
"1576","Ribavirin-induced anemia (NA)",1
"1577","RR interval (heart rate) (unit increase)",1
"1578","Sagittal craniosynostosis (NA)",2
"1579","Sarcoidosis (Chronic) (NA)",1
"1580","Sarcoidosis (NA)",1
"1581","Schizophrenia, bipolar disorder and depression (combined) (NA)",1
"1582","Schizophrenia (EA) (NA)",2
"1583","Schizophrenia (NA)",134
"1584","Schizophrenia or bipolar disorder (SCZ or BP vs. controls) (NA)",6
"1585","Schizophrenia, schizoaffective disorder or bipolar disorder (NA)",4
"1586","Sclerosing cholangitis and ulcerative colitis (combined) (NA)",2
"1587","Scoliosis (NA)",2
"1588","Select biomarker traits (CRP average 2,6,7) (NA)",1
"1589","Select biomarker traits (MCP1) (NA)",2
"1590","Self-reported allergy (unit increase)",15
"1591","Sensory disturbances after bilateral sagittal split ramus osteotomy (Hypoesthesia, Recessive) (NA)",1
"1592","Serum albumin level (NA)",1
"1593","Serum albumin level (unit increase) (EA) (unit increase)",1
"1594","Serum albumin level (unit increase) (unit increase)",5
"1595","Serum alkaline phosphatase levels (U/L increase)",3
"1596","Serum ceruloplasmin levels (mg/dl increase)",1
"1597","Serum dimethylarginine levels (asymmetric/symetric ratio) (unit increase)",2
"1598","Serum ferritin levels (unit increase)",1
"1599","Serum IgA levels (g/l increase)",1
"1600","Serum lipase activity (unit increase)",2
"1601","Serum metabolite levels (3-hydroxydecanoate) (unit increase)",1
"1602","Serum metabolite levels (Acetylcarnitine) (unit increase)",1
"1603","Serum metabolite levels (Aspartylphenylalanine) (unit increase)",1
"1604","Serum metabolite levels (Biliverdin) (unit increase)",1
"1605","Serum metabolite levels (Creatine) (unit increase)",1
"1606","Serum metabolite levels (Deoxycarnitine) (unit increase)",1
"1607","Serum metabolite levels (Hexadecanedioate) (unit increase)",1
"1608","Serum metabolite levels (HXGXA) (unit increase)",1
"1609","Serum metabolite levels (N-acetylornithine) (unit increase)",1
"1610","Serum metabolite levels (N-acetylphenylalanine) (unit increase)",1
"1611","Serum metabolite levels (Palmitoleate (16:1n7)) (unit increase)",1
"1612","Serum metabolite levels (Phenylacetate) (unit increase)",1
"1613","Serum metabolite levels (Trehalose) (unit increase)",1
"1614","Serum prostate-specific antigen levels (% increase) (% increase)",6
"1615","Serum prostate-specific antigen levels (NA)",1
"1616","Serum protein levels (sST2) (unit increase) (unit increase)",11
"1617","Serum thyroid-stimulating hormone levels (unit increase) (EA) (unit increase)",1
"1618","Serum thyroid-stimulating hormone levels (unit increase) (unit increase)",2
"1619","Serum total protein level (unit increase)",3
"1620","Serum uric acid levels (NA)",1
"1621","Serum uric acid levels (s.d. increase) (s.d. increase)",1
"1622","Serum uric acid levels (unit increase) (unit increase)",4
"1623","Serum VEGFR2 concentration (ng/mL increase)",1
"1624","Serum vitamin D-binding protein levels (nmol/L increase)",2
"1625","Sex hormone-binding globulin levels (nmol/L increase) (Men + Women) (nmol/L increase)",2
"1626","Sex hormone-binding globulin levels (umol/L increase) (Men) (umol/L increase)",2
"1627","Sex hormone-binding globulin levels (umol/L increase) (Men + Women) (umol/L increase)",7
"1628","Sex hormone-binding globulin levels (unit increase) (Men + Women, Conditional) (unit increase)",3
"1629","Sex hormone-binding globulin levels (unit increase) (unit increase)",1
"1630","Sexual dimorphism in anthropometric traits (WHRadjBMI, women) (NA)",3
"1631","Sickle cell anemia (haemolysis) (unit increase) (unit increase)",3
"1632","Sitting height ratio (EA) (unit increase)",1
"1633","Sitting height ratio (unit increase)",2
"1634","Sjögren's syndrome (NA)",5
"1635","Skin pigmentation (NA)",3
"1636","Skin sensitivity to sun (NA)",1
"1637","Sleep duration (EA) (unit increase)",1
"1638","Sleep duration (unit increase)",1
"1639","Sleep-related phenotypes (Sleepiness) (NA)",1
"1640","Smoking behavior (CPD increase) (CPD) (CPD increase)",3
"1641","Smoking behavior (CPD increase) (CPD increase)",2
"1642","Smoking behavior (smoking cessation) (NA)",1
"1643","Smoking behavior (smoking initiation) (NA)",1
"1644","Smoking behavior (unit increase) (CPD) (unit increase)",1
"1645","Smoking behavior (unit increase) (unit increase)",1
"1646","Social communication problems (Age 17) (unit increase)",1
"1647","Soluble E-selectin levels (NA)",1
"1648","Soluble ICAM-1 (ng/mL increase) (ng/mL increase)",2
"1649","Soluble ICAM-1 (umol/L increase) (umol/L increase)",1
"1650","Soluble leptin receptor levels (% increase)",1
"1651","Soluble levels of adhesion molecules (ICAM) (% increase)",2
"1652","Soluble levels of adhesion molecules (P-Selectin) (% increase)",3
"1653","Sphingolipid levels (% increase) (levels) (% increase)",8
"1654","Sphingolipid levels (% increase) (proportions) (% increase)",2
"1655","Sphingolipid levels (mol % increase) (SM 14:0Mol%) (mol % increase)",1
"1656","Sphingolipid levels (unit increase) (GluCer) (unit increase)",1
"1657","Sphingolipid levels (unit increase) (SM 16:1) (unit increase)",1
"1658","Spontaneous preterm birth (preterm birth) (NA)",1
"1659","Sporadic pituitary adenoma (NA)",1
"1660","Squamous cell carcinoma (NA)",1
"1661","Stearic acid (18:0) plasma levels (unit increase)",5
"1662","Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) (NA)",1
"1663","Stroke (ischemic) (CS) (NA)",2
"1664","Stroke (ischemic) (LVD) (NA)",1
"1665","Stroke (ischemic) (NA)",1
"1666","Stroke (LVD) (NA)",1
"1667","Stroke (NA)",1
"1668","Subcortical brain region volumes (mm3 increase) (Caudate, EA) (mm3 increase)",1
"1669","Subcortical brain region volumes (mm3 increase) (Hippocampus, EA) (mm3 increase)",2
"1670","Subcortical brain region volumes (mm3 increase) (Intracranial volume, EA) (mm3 increase)",1
"1671","Subcortical brain region volumes (mm3 increase) (Putamen, EA) (mm3 increase)",4
"1672","Subcortical brain region volumes (unit increase) (Hippocampus, EA) (unit increase)",1
"1673","Subcortical brain region volumes (unit increase) (Intracranial volume, EA) (unit increase)",1
"1674","Sudden cardiac arrest (NA)",1
"1675","Sudden cardiac arrest (Recessive) (NA)",12
"1676","Sunburns (unit increase)",2
"1677","Superior frontal gyrus grey matter volume (Right superior frontal gyrus) (unit increase)",1
"1678","Symmetrical dimethylarginine levels (unit increase)",4
"1679","Systemic lupus erythematosus and Systemic sclerosis (ACA) (NA)",1
"1680","Systemic lupus erythematosus and Systemic sclerosis (lcSSc) (NA)",1
"1681","Systemic lupus erythematosus and Systemic sclerosis (NA)",9
"1682","Systemic lupus erythematosus (anti-dsDNA -) (NA)",1
"1683","Systemic lupus erythematosus (anti-dsDNA +) (NA)",3
"1684","Systemic lupus erythematosus (NA)",54
"1685","Systemic sclerosis (ACA positive) (NA)",2
"1686","Systemic sclerosis (ATA positive) (NA)",4
"1687","Systemic sclerosis (IcSSc) (NA)",1
"1688","Systemic sclerosis (NA)",7
"1689","Systolic blood pressure (alcohol consumption interaction) (drinks/week) (unit increase)",1
"1690","Systolic blood pressure (mm Hg increase) (mm Hg increase)",6
"1691","Systolic blood pressure (mmHg increase) (mmHg increase)",18
"1692","Systolic blood pressure (unit increase) (unit increase)",10
"1693","Tanning (tanning ability score increase) (tanning ability score increase)",5
"1694","Tanning (unit increase) (unit increase)",5
"1695","Telomere length (kb increase) (kb increase)",1
"1696","Telomere length (unit increase) (unit increase)",9
"1697","Temperament (bipolar disorder) (Hyperthymic) (unit increase)",2
"1698","Temperament (bipolar disorder) (Irritable) (unit increase)",1
"1699","Testicular cancer (NA)",3
"1700","Testicular germ cell cancer (NA)",6
"1701","Testicular germ cell tumor (NA)",19
"1702","Testosterone levels (ng/dl increase) (ng/dl increase)",2
"1703","Tetralogy of Fallot (NA)",2
"1704","Thiazide-induced adverse metabolic effects in hypertensive patients (AA-triglyceride response) (mg/dL increase)",1
"1705","Thoracic aortic aneurysms and dissections (NA)",1
"1706","Thrombin generation potential phenotypes (min increase) (min increase)",1
"1707","Thrombin generation potential phenotypes (nM increase) (nM increase)",1
"1708","Thrombin generation potential phenotypes (nM/min increase) (nM/min increase)",1
"1709","Thyroid cancer (NA)",6
"1710","Thyroid cancer (Papillary, radiation-related) (NA)",1
"1711","Thyroid function (unit increase)",4
"1712","Thyroid hormone levels (FT4-Females) (unit increase)",1
"1713","Thyroid hormone levels (FT4) (unit increase)",4
"1714","Thyroid hormone levels (TSH - Males) (unit increase)",1
"1715","Thyroid hormone levels (TSH) (unit increase)",18
"1716","Thyroid peroxidase antibody levels (unit increase)",3
"1717","Thyroid peroxidase antibody positivity (NA)",4
"1718","Thyroid stimulating hormone (uIU/ml increase) (uIU/ml increase)",1
"1719","Thyroid volume (NA)",3
"1720","Thyroid volume (unit increase) (unit increase)",3
"1721","Thyrotoxic hypokalemic periodic paralysis (NA)",2
"1722","Toenail selenium levels (unit increase)",3
"1723","Total bilirubin levels in HIV-1 infection (unit increase)",9
"1724","Tourette syndrome (NA)",1
"1725","Trans fatty acid levels (Cis/trans-18:2, EA) (unit increase)",31
"1726","Trans fatty acid levels (Trans/trans-18:2, EA) (unit increase)",1
"1727","Triglycerides-Blood Pressure (TG-BP) (unit increase)",6
"1728","Triglycerides (% increase) (% increase)",3
"1729","Triglycerides (increase) (increase)",1
"1730","Triglycerides (mg/dl increase) (mg/dl increase)",5
"1731","Triglycerides (mg/dL increase) (mg/dL increase)",49
"1732","Triglycerides (NA)",10
"1733","Triglycerides (percentage SD increase) (percentage SD increase)",4
"1734","Triglycerides (s.d. increase) (s.d. increase)",11
"1735","Triglycerides (unit increase) (AA) (unit increase)",3
"1736","Triglycerides (unit increase) (Hispanic) (unit increase)",1
"1737","Triglycerides (unit increase) (unit increase)",7
"1738","Triglycerides (% variance) (HDL) (% variance)",1
"1739","Triglycerides (% variance) (LDL) (% variance)",1
"1740","Tuberculosis (binary model) (NA)",1
"1741","Tuberculosis (NA)",3
"1742","Tumor biomarkers (ng/ml increase) (AFP) (ng/ml increase)",2
"1743","Tumor biomarkers (ng/ml increase) (CEA) (ng/ml increase)",3
"1744","Tumor biomarkers (U/ml increase) (U/ml increase)",4
"1745","Two-hour glucose challenge (mmol/L increase)",3
"1746","Type 1 diabetes and autoimmune thyroid diseases (NA)",6
"1747","Type 1 diabetes autoantibodies (I-A2A) (NA)",1
"1748","Type 1 diabetes autoantibodies (T1D) (NA)",16
"1749","Type 1 diabetes (NA)",52
"1750","Type 1 diabetes nephropathy (ESRD vs. non-ESRD) (NA)",2
"1751","Type 2 diabetes (AA) (NA)",1
"1752","Type 2 diabetes and other traits (NA)",4
"1753","Type 2 diabetes (DGI+FUSION+WTCCC) (NA)",2
"1754","Type 2 diabetes (East Asian) (NA)",1
"1755","Type 2 diabetes (Indian) (NA)",1
"1756","Type 2 diabetes (Lean) (NA)",1
"1757","Type 2 diabetes (NA)",106
"1758","Type 2 diabetes (obese) (NA)",1
"1759","Type 2 diabetes (Obese) (NA)",2
"1760","Type 2 diabetes (Punjabi Sikhs) (NA)",1
"1761","Type 2 diabetes (South Asian, East Asian, Europeans) (NA)",1
"1762","Ulcerative colitis (Analysis III) (NA)",1
"1763","Ulcerative colitis (NA)",89
"1764","Ulcerative colitis or Crohn's disease (NA)",2
"1765","Upper aerodigestive tract cancers (NA)",4
"1766","Urate levels in lean individuals (kg/m2 increase)",1
"1767","Urate levels in lean individuals (Men) (kg/m2 increase)",2
"1768","Urate levels in lean individuals (Women) (kg/m2 increase)",1
"1769","Urate levels in obese individuals (kg/m2 increase)",1
"1770","Urate levels in obese individuals (women) (kg/m2 increase)",1
"1771","Urate levels in overweight individuals (kg/m2 increase)",3
"1772","Urate levels in overweight individuals (men) (kg/m2 increase)",3
"1773","Urate levels in overweight individuals (women) (kg/m2 increase)",1
"1774","Urate levels (mg/dl increase) (AA) (mg/dl increase)",4
"1775","Urate levels (mg/dl increase in uric acid) (mg/dl increase in uric acid)",1
"1776","Urate levels (mg/dl increase) (mg/dl increase)",29
"1777","Urate levels (mg/dl increase) (network) (mg/dl increase)",2
"1778","Urate levels (SD increase in serum uric acid level) (SD increase in serum uric acid level)",2
"1779","Urate levels (uM increase in uric acid) (uM increase in uric acid)",1
"1780","Urate levels (umol/l increase) (umol/l increase)",6
"1781","Urate levels (unit increase) (unit increase)",5
"1782","Uric acid levels (mg/dl increase in uric serum levels) (mg/dl increase in uric serum levels)",1
"1783","Uric acid levels (mg/dl increase) (men) (mg/dl increase)",1
"1784","Uric acid levels (mg/dl increase) (mg/dl increase)",7
"1785","Uric acid levels (mg/dl increase) (women) (mg/dl increase)",1
"1786","Uric acid levels (NA)",1
"1787","Uric acid levels (Non-obese) (NA)",1
"1788","Uric acid levels (umol/L increase) (umol/L increase)",1
"1789","Uric acid levels (unit increase) (unit increase)",1
"1790","Urinary albumin excretion (CKDGen) (CKDGen)",1
"1791","Urinary bladder cancer (NA)",3
"1792","Urinary metabolites (2-Hydroxyisobutyrate concentration) (NA)",1
"1793","Urinary metabolites (3-Aminoisobutyrate concentration) (NA)",1
"1794","Urinary metabolites (Alanine/N,N-dimethylglycine ratio) (NA)",1
"1795","Urinary metabolites (Formate/succinate ratio) (NA)",1
"1796","Urinary metabolites (H-NMR features) (0.8475, Unknown) (unit increase)",1
"1797","Urinary metabolites (H-NMR features) (0.8875, Unknown) (unit increase)",1
"1798","Urinary metabolites (H-NMR features) (1.2025, Aminoisobutyrate) (unit increase)",2
"1799","Urinary metabolites (H-NMR features) (1.2575, Fucose) (unit increase)",1
"1800","Urinary metabolites (H-NMR features) (1.3625, 2-Hydroxyisobutyrate) (unit increase)",1
"1801","Urinary metabolites (H-NMR features) (1.6975, N-Acetylated compunds) (unit increase)",1
"1802","Urinary metabolites (H-NMR features) (1.8025, Unknown) (unit increase)",1
"1803","Urinary metabolites (H-NMR features) (2.0375, N-Acetylated compunds) (unit increase)",1
"1804","Urinary metabolites (H-NMR features) (2.1875, Unknown) (unit increase)",1
"1805","Urinary metabolites (H-NMR features) (2.8575, Trimethylamine) (unit increase)",1
"1806","Urinary metabolites (H-NMR features) (2.8725, Trimethylamine) (unit increase)",1
"1807","Urinary metabolites (H-NMR features) (2.8825, Trimethylamine) (unit increase)",1
"1808","Urinary metabolites (H-NMR features) (3.0275, Aminoisobutyrate) (unit increase)",1
"1809","Urinary metabolites (H-NMR features) (3.0325, Lysine) (unit increase)",1
"1810","Urinary metabolites (H-NMR features) (3.0925, Aminoisobutyrate) (unit increase)",1
"1811","Urinary metabolites (H-NMR features) (5.1825, Unknown) (unit increase)",1
"1812","Urinary metabolites (H-NMR features) (5.2125, Fucose) (unit increase)",1
"1813","Urinary metabolites (H-NMR features) (5.2625, Unknown) (unit increase)",1
"1814","Urinary metabolites (Lysine/valine ratio) (NA)",1
"1815","Urinary uromodulin levels (unit increase)",3
"1816","Uterine fibroids (NA)",3
"1817","Vascular dementia (NA)",1
"1818","Vascular endothelial growth factor levels (NA)",4
"1819","Vaspin levels (unit increase)",1
"1820","Venous thromboembolism (NA)",17
"1821","Verbal declarative memory (PAR-dr, EA) (NA)",2
"1822","Verbal declarative memory (unit increase) (CERAD-dr) (unit increase)",1
"1823","Verbal declarative memory (unit increase) (CVLT-dr, EA) (unit increase)",1
"1824","Verbal declarative memory (unit increase) (RAVLT-dr, EA) (unit increase)",1
"1825","Vertical cup-disc ratio (mm2 increase) (mm2 increase)",6
"1826","Vertical cup-disc ratio (unit increase) (unit increase)",17
"1827","Very long-chain saturated fatty acid levels (fatty acid 20:0) (Z score increase)",3
"1828","Very long-chain saturated fatty acid levels (fatty acid 22:0) (Z score increase)",2
"1829","Very long-chain saturated fatty acid levels (fatty acid 24:0) (Z score increase)",2
"1830","Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia (NA)",5
"1831","Visceral adipose tissue/subcutaneous adipose tissue ratio (overall) (NA)",1
"1832","Visceral fat (women) (NA)",1
"1833","Vitamin B12 levels (pg/ml increase)",6
"1834","Vitamin B levels in ischemic stroke (Vitamin B12) (unit increase)",2
"1835","Vitamin B levels in ischemic stroke (Vitamin B6) (unit increase)",1
"1836","Vitamin D insufficiency (NA)",3
"1837","Vitamin D levels (unit increase) (Age 14) (unit increase)",3
"1838","Vitamin D levels (unit increase) (Age 6) (unit increase)",2
"1839","Vitamin D levels (unit increase) (unit increase)",3
"1840","Vitamin E levels (unit increase)",3
"1841","Vitiligo (NA)",29
"1842","Vitiligo (non-segmental) (NA)",1
"1843","Vogt-Koyanagi-Harada syndrome (NA)",3
"1844","Volumetric brain MRI (ATCBV) (NA)",1
"1845","vWF levels (unit increase)",2
"1846","Waist circumference and related phenotypes (cm increase) (cm increase)",1
"1847","Waist circumference and related phenotypes (HDL cholesterol) (NA)",1
"1848","Waist circumference and related phenotypes (triglycerides) (NA)",1
"1849","Waist circumference (NA)",1
"1850","Waist Circumference - Triglycerides (WC-TG) (unit increase)",7
"1851","Waist circumference (unit increase) (BMI_pooled) (unit increase)",1
"1852","Waist-hip ratio (NA)",3
"1853","Waist-hip ratio (unit increase) (BMI_pooled) (unit increase)",1
"1854","Waist-hip ratio (unit increase) (unit increase)",14
"1855","Waist-to-hip ratio adjusted for body mass index (EA) (unit increase)",3
"1856","Waist-to-hip ratio adjusted for body mass index (EA, women) (unit increase)",5
"1857","Waist-to-hip ratio adjusted for body mass index (men) (unit increase)",1
"1858","Waist-to-hip ratio adjusted for body mass index (unit increase)",9
"1859","Waist-to-hip ratio adjusted for body mass index (women) (unit increase)",6
"1860","Warfarin maintenance dose (mg/week increase) (mg/week increase)",4
"1861","Warfarin maintenance dose (NA)",3
"1862","Wegener's granulomatosis (NA)",2
"1863","Weight (percentage SD increase) (percentage SD increase)",11
"1864","White blood cell count (K/ul increase) (AA) (K/ul increase)",2
"1865","White blood cell count (K/ul increase) (EA) (K/ul increase)",1
"1866","White blood cell count (NA)",1
"1867","White blood cell count (unit increase) (AA) (unit increase)",1
"1868","White blood cell count (unit increase) (Basophils) (unit increase)",1
"1869","White blood cell count (unit increase) (Japanese) (unit increase)",2
"1870","White blood cell count (unit increase) (Lymphocytes) (unit increase)",2
"1871","White blood cell count (unit increase) (Monocytes) (unit increase)",4
"1872","White blood cell count (unit increase) (Neutrophils) (unit increase)",1
"1873","White blood cell count (unit increase) (unit increase)",9
"1874","White blood cell count (unit increase) (WBC) (unit increase)",2
"1875","White blood cell types (basophil count) (unit increase)",4
"1876","White blood cell types (eosinophil count) (unit increase)",2
"1877","White blood cell types (monocyte count) (unit increase)",4
"1878","White blood cell types (neutrophil count) (unit increase)",2
"1879","White matter hyperintensity burden (NA)",2
"1880","White matter microstructure (global fractional anisotropy) (NA)",5
"1881","White wine liking (unit increase)",1
"1882","Wilms tumor (NA)",6
"1883","YKL-40 levels (ng/ml increase)",1
